NZ614325B2 - Variants of human gdnf - Google Patents
Variants of human gdnf Download PDFInfo
- Publication number
- NZ614325B2 NZ614325B2 NZ614325A NZ61432512A NZ614325B2 NZ 614325 B2 NZ614325 B2 NZ 614325B2 NZ 614325 A NZ614325 A NZ 614325A NZ 61432512 A NZ61432512 A NZ 61432512A NZ 614325 B2 NZ614325 B2 NZ 614325B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- gdnf
- seq
- variant
- human
- human gdnf
- Prior art date
Links
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 68
- 102000004329 Glial cell line-derived neurotrophic factor Human genes 0.000 claims abstract description 16
- 108090000821 Glial cell line-derived neurotrophic factor Proteins 0.000 claims abstract description 16
- 206010061536 Parkinson's disease Diseases 0.000 claims abstract description 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 108060008201 GDNF Proteins 0.000 description 216
- 102100000369 GDNF Human genes 0.000 description 216
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 36
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 36
- 210000004027 cells Anatomy 0.000 description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- 102100019001 EIF3B Human genes 0.000 description 23
- 101700076086 EIF3B Proteins 0.000 description 23
- 101700010977 PRT1 Proteins 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 23
- 102200130778 LINS1 N38Q Human genes 0.000 description 22
- 230000028327 secretion Effects 0.000 description 22
- 210000004556 Brain Anatomy 0.000 description 21
- 241000588724 Escherichia coli Species 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 21
- 238000001802 infusion Methods 0.000 description 19
- 241000700159 Rattus Species 0.000 description 18
- 229960003638 dopamine Drugs 0.000 description 18
- 239000011780 sodium chloride Substances 0.000 description 18
- 239000011534 wash buffer Substances 0.000 description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 102200070243 SIRPA D95E Human genes 0.000 description 14
- 239000002609 media Substances 0.000 description 13
- 230000037177 Biodistribution Effects 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 238000005277 cation exchange chromatography Methods 0.000 description 11
- 102000008000 human cationic antimicrobial protein CAP 37 Human genes 0.000 description 11
- 108010089633 human cationic antimicrobial protein CAP 37 Proteins 0.000 description 11
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 10
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 10
- 230000000903 blocking Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 229960002897 Heparin Drugs 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 9
- 238000004166 bioassay Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 229920000669 heparin Polymers 0.000 description 9
- QRMZSPFSDQBLIX-UHFFFAOYSA-N Homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 8
- 102000000813 Proto-Oncogene Proteins c-ret Human genes 0.000 description 8
- 108010001648 Proto-Oncogene Proteins c-ret Proteins 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 230000002829 reduced Effects 0.000 description 8
- 210000001519 tissues Anatomy 0.000 description 8
- 108090001123 antibodies Proteins 0.000 description 7
- 102000004965 antibodies Human genes 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 230000014511 neuron projection development Effects 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 230000000865 phosphorylative Effects 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 210000003128 Head Anatomy 0.000 description 6
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 6
- DIVDFFZHCJEHGG-UHFFFAOYSA-N Oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 6
- VLTRZXGMWDSKGL-UHFFFAOYSA-N Perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 229960002725 isoflurane Drugs 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 238000001542 size-exclusion chromatography Methods 0.000 description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 6
- 239000001632 sodium acetate Substances 0.000 description 6
- 235000017281 sodium acetate Nutrition 0.000 description 6
- 210000001159 Caudate Nucleus Anatomy 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 239000000854 Human Growth Hormone Substances 0.000 description 5
- 102000002265 Human Growth Hormone Human genes 0.000 description 5
- 108010000521 Human Growth Hormone Proteins 0.000 description 5
- 229920001850 Nucleic acid sequence Polymers 0.000 description 5
- 230000001580 bacterial Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 239000001963 growth media Substances 0.000 description 5
- 238000006317 isomerization reaction Methods 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 4
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 4
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 4
- 229920000453 Consensus sequence Polymers 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000003155 DNA primer Substances 0.000 description 3
- 101000070729 GFRA1 Proteins 0.000 description 3
- 229960004198 Guanidine Drugs 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N Kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 101710010796 LYZ Proteins 0.000 description 3
- 229910004682 ON-OFF Inorganic materials 0.000 description 3
- 229940100655 Ophthalmic Gel Drugs 0.000 description 3
- 210000004761 Scalp Anatomy 0.000 description 3
- 210000003625 Skull Anatomy 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 210000003523 Substantia Nigra Anatomy 0.000 description 3
- 238000001949 anaesthesia Methods 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000000202 analgesic Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000004059 degradation Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000003899 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 102000020724 human GFRA1 protein Human genes 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000002980 postoperative Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- CIWBSHSKHKDKBQ-DUZGATOHSA-N (+)-Ascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 2
- AFYNADDZULBEJA-UHFFFAOYSA-N Bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 2
- 101700023299 CATC Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- 210000004379 Membranes Anatomy 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 102200039786 NUAK1 K84A Human genes 0.000 description 2
- 210000004940 Nucleus Anatomy 0.000 description 2
- 229920000272 Oligonucleotide Polymers 0.000 description 2
- 241001191345 Osa Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N Succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 238000004164 analytical calibration Methods 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 238000002144 chemical decomposition reaction Methods 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 229960005188 collagen Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 230000003291 dopaminomimetic Effects 0.000 description 2
- 238000000835 electrochemical detection Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 102000005396 glutamine synthetase family Human genes 0.000 description 2
- 108020002326 glutamine synthetase family Proteins 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 239000011539 homogenization buffer Substances 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 210000004962 mammalian cells Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 238000003522 neurite outgrowth assay Methods 0.000 description 2
- 230000004031 neuronal differentiation Effects 0.000 description 2
- 210000002569 neurons Anatomy 0.000 description 2
- 230000000324 neuroprotective Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 108091008117 polyclonal antibodies Proteins 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Inorganic materials [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229960002317 succinimide Drugs 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000009966 trimming Methods 0.000 description 2
- 239000011778 trisodium citrate Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- 102100012672 ARTN Human genes 0.000 description 1
- 101700061329 ARTN Proteins 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 229920002287 Amplicon Polymers 0.000 description 1
- 206010002368 Anger Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N Bis-tris methane Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 210000001638 Cerebellum Anatomy 0.000 description 1
- 210000004720 Cerebrum Anatomy 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 240000006497 Dianthus caryophyllus Species 0.000 description 1
- 235000009355 Dianthus caryophyllus Nutrition 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 229940088598 Enzyme Drugs 0.000 description 1
- 210000002744 Extracellular Matrix Anatomy 0.000 description 1
- 101000126512 GDNF Proteins 0.000 description 1
- 102000024926 GDNF family Human genes 0.000 description 1
- 108091020536 GDNF family Proteins 0.000 description 1
- 229960001269 Glycine Hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N Guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- WZUVPPKBWHMQCE-VYIIXAMBSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@@]2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-VYIIXAMBSA-N 0.000 description 1
- 210000003000 Inclusion Bodies Anatomy 0.000 description 1
- 210000004347 Intestinal Mucosa Anatomy 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical group OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102100005410 LINE-1 retrotransposable element ORF2 protein Human genes 0.000 description 1
- 229950009101 Liatermin Drugs 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-β-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 102400000108 N-terminal peptide Human genes 0.000 description 1
- 101800000597 N-terminal peptide Proteins 0.000 description 1
- 101700009327 NTF3 Proteins 0.000 description 1
- 229940060155 Neuac Drugs 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 210000000956 Olfactory Bulb Anatomy 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102000004097 Protein phosphatase inhibitor 1 Human genes 0.000 description 1
- 108090000506 Protein phosphatase inhibitor 1 Proteins 0.000 description 1
- 210000002637 Putamen Anatomy 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229940076185 Staphylococcus aureus Drugs 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102220385055 VPS45 R88K Human genes 0.000 description 1
- 102220385029 VPS45 R90K Human genes 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 238000009632 agar plate Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000692 anti-sense Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 230000001174 ascending Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960000074 biopharmaceuticals Drugs 0.000 description 1
- 230000037348 biosynthesis Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- ANUSOIHIIPAHJV-UHFFFAOYSA-N fenticlor Chemical compound OC1=CC=C(Cl)C=C1SC1=CC(Cl)=CC=C1O ANUSOIHIIPAHJV-UHFFFAOYSA-N 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 102000026452 human GDNF protein Human genes 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl β-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000002045 lasting Effects 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 101710030587 ligN Proteins 0.000 description 1
- 101700077585 ligd Proteins 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000002934 lysing Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- 102000005614 monoclonal antibodies Human genes 0.000 description 1
- 230000001537 neural Effects 0.000 description 1
- 230000017308 neuron projection morphogenesis Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 101710015766 ngl Proteins 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000003566 phosphorylation assay Methods 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 108091007521 restriction endonucleases Proteins 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 230000001228 trophic Effects 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
Abstract
Disclosed is a human GDNF variant comprising the amino acid sequence of SEQ ID NO:23 and its use in treating Parkinson's disease, wherein the sequence is as defined in the specification.
Description
VARIANTS OF HUMAN GDNF
The present invention is in the field of medicine, particularly in the field of
therapeutic proteins. Specifically, the present invention relates to novel variants of
human glial cell-derived neurotrophic factor (GDNF). The novel variants of GDNF may
be useful for the treatment of Parkinson’s disease.
GDNF is a well known neurotrophic factor that is reported to provide trophic
support to dopaminergic neurons in vitro and in vivo. Further, it has been reported that
GDNF provides functional improvements and has neuroprotective actions in rodent and
primate models of Parkinson's disease. Wild type GDNF protein from E. coli has been
administered centrally to patients suffering from Parkinson’s disease with mixed results.
In two small open labeled studies, the wild type GDNF was reported to produce long-
lasting improvement in motor function. However, in a randomized, placebo-controlled,
Phase IIa trial of 34 patients, intra-putamenal delivery of GDNF showed no symptomatic
improvement at 6 months. An increase in biomarker signal was only evident in the
immediate tissue surrounding the infusion site. One recent report states that GDNF may
be a promising molecule to rescue dying nerves; however, delivering the molecule to the
correct area of the brain remains a daunting challenge. Nature, Vol 466:19 August 2010.
Truncated GDNF proteins are reported in WO97/11964 (PCT/US96/14915);
however, there continues to be a need for new GDNF variants with desired
pharmacological properties, stability and bio-distribution properties. There is a need for a
variant form of GDNF that is stable in the delivery device, and facilitates desired brain
bio-distribution, while demonstrating desired potency and acceptable immunogenicity
properties. GDNF variants offering one or more of these desirable properties may be a
new pharmaceutically useful medicinal therapy, particularly for use in the treatment of
Parkinson’s disease.
The present invention provides a novel truncated GDNF variant of mature human
GDNF domain lacking the first 31 amino acids at the N-terminus (“∆31-N-terminus
truncated GDNF”), with certain amino acid substitutions introduced to provide stable,
suitably potent, GDNF variants offering desirable bio-distribution properties and a
pharmaceutically acceptable immunogenicity profile. The present invention provides
certain variants of human GDNF that impart one or more advantages over mature human
wild-type GDNF including variants that have improved pharmaceutical stability, as well
as improved bio-distribution, reduced heparin binding, reduced deamidation, reduced
susceptibility to succinimide formation, and reduced immunogenicity potential compared
to human wild-type GDNF and/or at least provides the public with a useful choice.
Certain new GDNF variants may be a useful new treatment option for Parkinson’s disease
patients.
In one aspect the present invention provides human GDNF variant comprising
SEQ ID NO: 23:
RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYDKILXaa
NLSXaa NXaa RLVSEKVGQACCRPIAFDDDLSFLDDNLVYHILRXaa HSAKXaa
88 90 125
CGCI (SEQ ID NO: 23), wherein:
i) Xaa is K or A;
ii) Xaa is R or K;
iii) Xaa is R or K;
iv) Xaa is K or E; and
v) Xaa is R or E.
The invention further provides a human GDNF variant wherein said variant is
selected from the group consisting of
RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYDKILKNL
SRNRRLVSEKVGQACCRPIAFDDDLSFLDDNLVYHILRKHSAKRCGCI (SEQ ID
NO:9),
RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYDKILANL
SKNKRLVSEKVGQACCRPIAFDDDLSFLDDNLVYHILRKHSAKRCGCI (SEQ ID
NO:12), and
RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYDKILANL
SKNKRLVSEKVGQACCRPIAFDDDLSFLDDNLVYHILREHSAKECGCI (SEQ ID
NO:15).
In an aspect, the invention provides a human GDNF variant comprising an amino
acid sequence as shown in SEQ ID NO: 9:
RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYDKILKNL
SRNRRLVSEKVGQACCRPIAFDDDLSFLDDNLVYHILRKHSAKRCGCI.
Also described herein is an intermediate, useful for preparing a ∆31-N-terminus
truncated variant of mature human GDNF. The intermediate comprises the amino acid
sequence of SEQ ID NO: 23
RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYDKILXaa
NLSXaa NXaa RLVSEKVGQACCRPIAFDDDLSFLDDNLVYHILRXaa HSAKXaa
88 90 125
CGCI (SEQ ID NO: 23), which is extended at the N-terminus with a signal secretion
peptide. Numbers of signal secretion peptide sequences can be used herein. Exemplary
signal secretion peptide sequences include murine kappa leader signal secretion peptide
having a sequence of METDTLLLWVLLLWVPGSTG (SEQ ID NO: 25), and human
growth hormone signal secretion peptide having a sequence of
MATGSRTSLLLAFGLLCLPWLQEGSA (SEQ ID NO: 32).
Intermediates having these signal secretion peptides can produce the claimed
human GDNF variants with increased yield over truncated GDNF constructs having other
leader sequences. The disclosed intermediates including signal secretion peptide can thus
have an amino acid sequence of
METDTLLLWVLLLWVPGSTGRGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIF
RYCSGSCDAAETTYDKILKNLSRNRRLVSEKVGQACCRPIAFDDDLSFLDDNLVY
HILRKHSAKRCGCI (SEQ ID NO: 28); or
MATGSRTSLLLAFGLLCLPWLQEGSARGQRGKQRGCVLTAIHLNVTDLGLGYET
KEELIFRYCSGSCDAAETTYDKILKNLSRNRRLVSEKVGQACCRPIAFDDDLSFLD
DNLVYHILRKHSAKRCGCI (SEQ ID NO: 35).
In one aspect the present invention relates to a compound comprising an amino
acid sequence selected from the group consisting of
METDTLLLWVLLLWVPGSTGRGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIF
RYCSGSCDAAETTYDKILKNLSRNRRLVSEKVGQACCRPIAFDDDLSFLDDNLVY
HILRKHSAKRCGCI (SEQ ID NO: 28); and
MATGSRTSLLLAFGLLCLPWLQEGSARGQRGKQRGCVLTAIHLNVTDLGLGYET
KEELIFRYCSGSCDAAETTYDKILKNLSRNRRLVSEKVGQACCRPIAFDDDLSFLD
DNLVYHILRKHSAKRCGCI (SEQ ID NO: 35).
The invention also provides a pharmaceutical composition, comprising a variant
of human GDNF of the present invention and one or more pharmaceutically acceptable
diluents, carriers or excipients.
In another aspect the invention provides for the use of a human GDNF variant as
defined in the invention in the manufacture of a medicament for treating Parkinson’s
disease in a human patient in need thereof.
In another aspect the invention provides for the use of a human GDNF variant as
defined in the invention in the manufacture of a medicament for treating Parkinson’s
disease in a mammal.
The invention provides a variant of human GDNF of the invention for use as a
medicament. The invention further provides a variant of human GDNF of the invention
for use in the treatment of Parkinson’s disease. The invention provides a variant of
GDNF for use as a therapy.
A variant wherein Xaa is A, Xaa is K, and Xaa is K is preferred.
84 88 90
A variant wherein Xaa is K, Xaa is R, and Xaa is R is preferred.
84 88 90
A variant wherein Xaa is K and Xaa is R is preferred.
125 130
A variant wherein Xaa is A, Xaa is K, and Xaa is K, Xaa is E and Xaa is E
84 88 90 125 130
is preferred.
Certain statements that appear below are broader than what appears in the
statements of the invention above. These statements are provided in the interests of
providing the reader with a better understanding of the invention and its practice. The
reader is directed to the accompanying claim set which defines the scope of the invention.
DETAILED DESCRIPTION
It has been reported that wild type GDNF binds to heparin and extracellular
matrix, likely through the positive charges located in the N-terminal 1-31 amino acid
residues, therefore limiting the distribution of GDNF upon delivery in the brain (Lin et
al., J Neurochem 63, 758-768, 1994; Rickard et al., Glycobiology 13, 419-426, 2003;
Piltonen et al., Experimental Neurology 219, 499-506, 2009) . It has also been reported
that GDNF provides functional improvements and has neuroprotective actions in rodent
and primate models of Parkinson's disease (Tomac et al, 1995; Gash et al., 1996). Wild
type GDNF protein from E. coli has been administered centrally to patients suffering
from Parkinson’s disease with mixed results. In two small open labelled studies, GDNF
produced long-lasting improvement in motor function (Gill et al., 2003, Slevin et al.,
2005). In addition, increased dopaminergic neuron sprouting was evident in one patient
who died of unrelated causes – myocardial infarction (Love et al 2005). However, in a
randomized, placebo-controlled, Phase IIa trial of 34 patients conducted by Amgen, intra-
putamen delivery of GDNF (Liatermin) showed no symptomatic improvement at 6
months (Lang et al., 2006). The claimed GDNF variants exhibit improved properties
compared to the previously tested wild type GDNF protein from E. coli.
Wild type GDNF full length construct sequence (211aa) containing the signal
peptide (the first 19 amino acids, SEQ ID NO: 4), pro-domain (italics, SEQ ID NO: 5),
and mature peptide (underlined, SEQ ID NO: 3) is indicated as SEQ ID NO: 1:
MKLWDVVAVCLVLLHTASAFPLPAGKRPPEAPAEDRSLGRRRAPFALSSDSNMPE
DYPDQFDDVMDFIQATIKRLKRSPDKQMAVLPRRERNRQAAAANPENSRGKGRR
GQRGKNRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYDKILKNLS
RNRRLVSDKVGQACCRPIAFDDDLSFLDDNLVYHILRKHSAKRCGCI. The wild
type GDNF full length DNA sequence is indicated as SEQ ID NO: 2:
ATGAAGCTGTGGGACGTGGTGGCCGTGTGCCTGGTGCTGCTGCACACCGCCA
GCGCTTTCCCACTGCCAGCCGGCAAGAGACCCCCAGAGGCCCCAGCCGAGGA
CAGAAGCCTGGGCAGGCGGAGGGCCCCATTCGCCCTGAGCAGCGACAGCAAC
ATGCCAGAGGACTACCCCGACCAGTTCGACGACGTCATGGACTTCATCCAGG
CCACCATCAAGAGGCTGAAGAGGTCACCCGACAAGCAGATGGCCGTGCTGCC
CAGGCGGGAGAGGAACAGGCAGGCCGCCGCCGCCAACCCAGAGAATTCCAG
GGGCAAGGGCAGAAGGGGTCAACGGGGCAAGAACAGGGGCTGCGTGCTGAC
CGCCATCCACCTGAACGTGACCGACCTGGGCCTGGGCTACGAGACCAAGGAG
GAGCTGATCTTCAGGTACTGCAGCGGCAGCTGCGACGCCGCCGAGACCACCT
ACGACAAGATCCTGAAGAACCTGAGCAGGAACAGGCGGCTGGTCTCCGACAA
GGTGGGCCAGGCCTGCTGCAGGCCCATCGCCTTCGACGACGACCTGAGCTTC
CTGGACGACAACCTGGTGTACCACATCCTGAGGAAGCACAGCGCCAAGAGAT
GCGGCTGCATC.
The amino acid positions of the variants of the present invention are determined
from the 134 amino acid polypeptide of mature human wild type GDNF (SEQ ID NO: 3).
Mutations are designated by the original amino acid, followed by the number of the
amino acid position, followed by the replacement amino acid. The numerical designation
of each variant is based on wild type mature sequence (“mature WT GDNF”) before
truncation. For example, a substitution for Lys (K) at position 84 (i.e. K84) with Ala (A)
is designated as K84A. In a similar fashion, the multiple substitutions for Lys (K) at
position 84 with Ala (A), Arg (R) at position 88 with Lys (K), Arg (R) at position 90 with
Lys (K) and Asp (D) at position 95 with Glu (E) is designated as
K84A/R88K/R90K/D95E. As used herein the abbreviation “KAKKE” refers to K84A-
R88K-R90K-D95E.
As used herein, “full length GDNF” refers to the full protein sequence, including
signal peptide, prodomain, and mature domain.
As used herein, “mature GDNF” or “full length mature GDNF” refers to the full
GDNF mature domain (with signal peptide and prodomain cleaved off).
As used herein, “∆31-N-terminus truncated GDNF” refers to GDNF mature
domain lacking the first 31 amino acids at the N-terminus. As used herein, “∆31-N-
terminus truncated GDNF” and “human GDNF variant” (or “GDNFv”) are used
interchangeably.
Full length GDNF constructs when transfected in HEK293 cells over 5 days
produce predominantly full length mature GDNF. When full length GDNF constructs are
transfected in CHO cells over a longer period of time and during stable cell-line
generation, truncated forms of GDNF are the predominant forms (Lin et al., Science 260,
1130-1132, 1993). Delta31 (“∆31”), a truncated variant form of mature human GDNF in
which amino acid residues number 1 through 31 have been deleted at the N-terminus, has
SEQ ID NO: 8, and can be purified from the mixture.
The N-terminus truncated ∆31 GDNF variant can be produced in a mammalian or
bacterial expression system by deleting both the prodomain peptide sequence and the first
31 amino acid residues of the mature GDNF peptide at the DNA level, and using a
number of secretion signal sequence peptides, such as native GDNF secretion signal
peptide (SEQ ID NO: 4: MKLWDVVAVCLVLLHTASA); murine kappa leader
secretion signal peptide (SEQ ID NO: 25: METDTLLLWVLLLWVPGSTG); and human
growth hormone secretion signal peptide (SEQ ID NO: 32:
MATGSRTSLLLAFGLLCLPWLQEGSA). These constructs can produce single species
homogenous ∆31-N-terminus truncated GDNF variants.
One of ordinary skill in the art would understand that the claimed GDNF variants
do not exclude the possibility of glycosylation. The claimed GDNF variants can be
glycosylated as appropriate, depending on the expression system used. For example,
mammalian expressed GDNF variants are glycosylated at position N49 while bacterial
expressed variants are not.
When full length native sequence construct is used (SEQ ID NO: 2) during
expression, a mixture of GDNF species with various N-terminal truncations are produced
as well as mature form (non-truncated) with or without the prodomain region.
The following examples, performed essentially as described below, may be used
to assess certain characteristics of human GDNF variants of the invention.
Example 1
Protein Expression, Purification and Immunogenicity Analysis
a. Sub-cloning, Mutation, Expression, Unfolding, Re-folding, and Purification of
E. coli-expressed GDNFv
Sub-cloning. E. coli strain BL21-CodonPlus (DE3)-RIPL harboring plasmid pET-
30a(+)/rhGDNF is grown on Luria–Bertani broth medium containing kanamycin at a final
concentration of 30 µg/ml overnight at 37 °C. After harvesting the cells by centrifugation
the plasmid vector is isolated by using a QIAquick Spin Miniprep kit (Qiagen) following
the manufacturer’s protocol. The isolated plasmid DNA is then used for primer extension
reaction of the ∆31-GDNF and ∆31-N38Q-GDNF genes encoding for ∆31-GDNF protein (
31 residues truncated from the N-terminus of mature human GDNF) and ∆31-N38Q-GDNF
protein (31 residues truncated from the N-terminus of mature human GDNF in which the
aspargine residue at position 38 is substituted by glutamine), respectively. This may be
accomplished using the oligonucleotide primers ∆31-for, ∆31-rev, ∆31-N38Q-for, and ∆31-
N38Q-rev (SEQ ID NOs:6, 7, 39, and 40, respectively) containing NdeI and XhoI restriction
endonuclease sites designed to anneal to the 5 and 3 ends of the gene. The NdeI and XhoI
restriction sites introduced at the 5 ends of the sense and antisense primers allow cloning of
∆31-GDNF and ∆31-N38Q-GDNF into the corresponding sites of the vector pET-30a(+).
Primer extension reaction is performed for 3 min at 94 °C, followed by 16 three-step cycles
of 1 min at 94 °C, 0.5 min at 55 °C, and 1 min at 72 °C, with a final 10 min step at 72 °C, in
a total volume of 100 µl by using 80 ng template DNA, forward and reverse primers, and
PCR Supermix (Invitrogen #10572-014). The resulting amplicons are verified on agarose
gel electrophoresis and cleaned using QIAquick PCR purification kit (Qiagen) following
the manufacturer’s protocol.
Both the amplified ∆31-GDNF or ∆31-N38Q-GDNF gene and pET-30a(+) vector are
digested for 2 h at 37 °C with NdeI and XhoI, followed by purification of the DNA by
agarose gel electrophoresis using the QIAquick Gel Extraction kit. The ∆31-GDNF or
∆31-N38Q-GDNF is then ligated into the pET-30a(+) plasmid using T4 DNA ligase and
following the manufacturer’s protocol. 2-5 µl of the ligation reaction mixtures is used to
transform directly 50-100 µl of E. coli strain BL21-CodonPlus (DE3)-RIPL chemically
competent cells following the manufacturer’s protocol (Agilent #230280). The resulting
transformant colonies obtained by plating on Luria–Bertani agar plates containing
kanamycin at a final concentration of 30 µg/ml are screened for the presence of correct
construct through sequencing the extracted plasmid in both directions by using the standard
T7 promotor and T7 terminator oligonucleotide primers.
Mutations. Site-directed mutagenesis is carried out using a QuikChange Multi Site-
Directed Mutagenesis kit (Stratagene, La Jolla, CA) to prepare ∆31-N38Q-D95E-GDNF
and ∆31-N38Q-K84A-R88K-R90K-D95E-GDNF. The method uses ∆31-N38Q-GDNF,
inserted into pET-30a(+)as a template, and ∆31-N38Q-D95E-for and ∆31-N38Q-D95E-rev
oligonucleotides (Table 1, SEQ ID NOs:41and 42) as forward and reverse primers,
respectively. Subsequently, the successfully mutated ∆31-N38Q-D95E gene inserted into
pET-30a(+) is used as a template, and ∆31-N38Q-K84A-R88K-R90K-D95E-for and ∆31-
K84A-R88K-R90K-D95E-D95E-rev oligonucleotides (Table 1, SEQ ID NOs:43 and 44) as
forward and reverse primers, respectively, to produce ∆31-N38Q-K84A-R88K-R90K-
D95E-GDNF. The DNA sequence is confirmed and the plasmid is transformed into E. coli
strain BL21-CodonPlus (DE3)-RIPL chemically competent cells.
Protein Expression. Permanent frozen stocks of E. coli cells BL21-CodonPlus (DE3)-
RIPL harboring plasmid pET-30a(+)/GDNFv are used to inoculate 50 ml of 2xTY broth
medium containing kanamycin at final concentrations of 30 µg/ml, at 37 °C. After 9 h,
ml of the starter culture is used to inoculate 6 × 2 liters of the same liquid culture medium
at 37 °C. When the culture reaches an optical density at 600 nm between 0.8 and 1.4,
typically after 16 h, IPTG is added to a final concentration of 1 mM and the temperature of
the culture is lowered between 27 and 30 °C for 5 h. Cells are harvested by centrifugation at
10,000g for 20 min at 4 °C and stored at −80 °C.
Solubilization-Re-folding. The cell paste is suspended in 2-3 volumes of a solution of
0.2 mg/ml lysozyme, 5mM MgCl and 50 mM Tris-Cl at pH 8 and allowed to incubate with
stirring for 30 min on ice. The resulting slurry is sonicated on ice for 10 min (5 sec pulses,
2 sec interval, 30-40% amplitude). Thereafter, GDNFv is recovered in the form of
inclusion bodies which are isolated from cell lysate by centrifugation at 20,000g for 20 min
and solubilized in 4M guanidine, 90 mM cysteine, 20 mM Tris-Cl, pH 8.5. The protein is
re-folded to the active form by 10X dilution with 0.2 M guanidine, 2M urea, 20 mM Tris-
Cl, pH 8.75. The refold mixture is held at 4° C. for 2 days.
Purification. The refolded GDNFv is purified to homogeneity through 3-steps of column
chromatography:
1. Cation Exchange Chromatography (CEX) on SP column
2. Hydrophobic Interaction Chromatography (HIC) on Phenyl column
3. Size Exclusion Chromatography (SEC) on Superdex-75 column.
The re-natured protein is firstly applied to an SP Sepharose fast flow column equilibrated
in 20 mM sodium acetate, pH 5. GDNFv is eluted with an ascending linear salt gradient
from 0.3 to 1 M NaCl in 20 mM sodium acetate, pH 5. The CEX mainstream pool is
supplemented with NaCl to a final concentration of 2.5 M and then applied to a Phenyl
Sepharose HP hydrophobic interaction chromatography column in 20 mM sodium citrate,
pH 5. The HIC column is eluted with a descending linear salt gradient from 2.5 to 0 M
NaCl in 20 mM sodium citrate, pH 5. GDNFv binds tightly to HIC column. The HIC
mainstream pool is then concentrated and finally applied to a Superdex-75 column and
the protein is eluted with PBS, pH 7.4. The final pool is concentrated, filtered through a
0.22 micron membrane and stored at -80 °C.
b. Expression and Purification of GDNFv in Mammalian Cells
Genes encoding GDNF variants may be prepared using standard molecular biology
techniques or by gene synthesis in a CMV promoter driven mammalian expression
vector. The recombinant plasmids are used to transiently transfect human embryonic
kidney 293EBNA (HEK293) cells and media is harvested after 5 days. In another
method, stable Chinese hamster ovary (CHO) cell lines are generated to express GDNF
variants. Genes coding for the variant proteins are subcloned into the Glutamine
Synthetase (GS)-containing expression plasmid backbones (pEE12.4-based plasmids,
Lonza Biologics, Slough, UK) in frame with the native GDNF signal sequence with pro-
domain according to the manufacturer’s instructions. Full length GDNF constructs (SEQ
ID NO: 2) in pEE12.4 based vectors are transfected in CHO and produce truncated forms
of GDNF where ∆31 is the predominant forms and can be purified from the mixture.
When the pro-domain and the first N-terminus 31 amino acids are removed, then the ∆31-
N-terminus truncated GDNF variant is produced efficiently and cleanly in a mammalian
expression system without the need for purification from a mixture of full length and
truncated products as reported previously. The native GDNF secretion signal peptide may
also be replaced with numbers of secretion signal peptides, including murine kappa
leader secretion signal peptide or human growth hormone secretion signal peptide. The
∆31-N-terminus truncated GDNF variant is still produced efficiently and cleanly with all
the disclosed secretion signal peptides but with variable levels of expression. GDNF
variants incorporating desired mutations are subcloned into suitable expression vectors
(such as pEMK-NF2, Lonza) in frame with the murine kappa signal sequence.
Purification. GDNFv is purified to homogeneity through 4-step bead
chromatography:
1. Cation Exchange Chromatography (CEX) on SP column
2. Hydrophobic Interaction Chromatography (HIC) on Phenyl column
3. Cation Exchange Chromatography (CEX) on multimodel Capto MMC column
4. Size Exclusion Chromatography (SEC) on Superdex-75 column.
Briefly, the harvested culture media containing GDNF variant proteins is firstly applied to
an SP Sepharose fast flow column equilibrated in 20 mM sodium acetate, pH 5. GDNFv
is eluted with a linear salt gradient from 0 to 1M NaCl in 20 mM sodium acetate, pH 5.
The CEX mainstream pool is supplemented with NaCl to a final concentration of 2.5 M
and then applied to a Phenyl Sepharose HP hydrophobic interaction chromatography
column in 20 mM sodium acetate, pH 5. The HIC column is eluted with a reversed linear
salt gradient from 2.5 to 0 M NaCl in 20 mM sodium acetate, pH 5. GDNFv binds
weakly to HIC column. A pool of the flow through and early elution fractions is then
applied to the multimodel resin of Capto MMC column at pH 5. The column is washed
with 50 mM Tris-Cl, pH 8, and then GDNFv is eluted with a linear salt gradient from 0 to
1 M NaCl in 50 mM Tris-Cl, pH 8. The Capto MMC mainstream is finally applied to a
Superdex-75 column and the protein is eluted with PBS, pH 7.4. The final pool is filtered
through a 0.22 micron membrane and stored at 2-8 °C.
Table 1. Oligonucleotide Primers Used for PCR and Site-directed Mutagenesis
Primer Nucleotide sequence Purpose
’TATACATATGCGTGGACAACGTGGTAAAAACCGTGGTTGTGTGCT
∆31-for PCR
G-3’ (SEQ ID No: 6)
’-GGTGCTCGAGTTATTAAATGCAGCCGCAACGTTTCGCGCT-3’
∆31-rev PCR
(SEQ ID No: 7)
∆31-N38Q-for TATACATATGCGTGGACAACGTGGTAAACAACGTGGTTGTGTGCTG PCR
-3’ (SEQ ID No: 39)
’-GGTGCTCGAGTTATTAAATGCAGCCGCAACGTTTCGCGCT-3’
∆31-N38Q-rev PCR
(SEQ ID No: 40)
∆31-N38Q-D95E-for 5’-GTCTGGTGAGCGAGAAAGTGGGTCAG-3’ (SEQ ID No: 41) Mutagenesis
∆31-N38Q-D95E-rev 5’-CTGACCCACTTTCTCGCTCACCAGAC-3’ (SEQ ID No: 42) Mutagenesis
∆31-N38Q-KAKKE-
CCTATGATAAAATCCTGGCAAACCTGAGCAAGAACAAACGTCTGG Mutagenesis
TGAGCGAGAAAG-3’ (SEQ ID No: 43)
∆31-N38Q-KAKKE-
CTTTCTCGCTCACCAGACGTTTGTTCTTGCTCAGGTTTGCCAGGATT Mutagenesis
TTATCATAGG-3’ (SEQ ID No: 44)
Endonuclease restriction sites for NdeI and XhoI enzymes are italicized. Underlined letters indicate
mismatches.
Epivax analysis of immunogenicity potential
Selected human GDNF variants with a reduced probability of binding HLA-DR
are made (SEQ ID NOs: 12 and 15) and compared to wild type GDNF in the GFRα and
heparin binding assay.
Example 2
Stability of GDNF wildtype and Δ Δ Δ Δ31 GDNF variant
The stability of the full length mature GDNF wildtype and the ∆31-N-terminus truncated
GDNF variants may be assessed using a number of analytical techniques such as RP-
HPLC, SE-HPLC, Cation Exchange HPLC, and mass spectrometry to identify any
degradation sites in these molecules. Mutations are then made to remove the chemical
degradation sites to improve stability of human GDNF variant.
Analytical reverse phase chromatography (RP-HPLC). On Zorbax C SB-300Å, 3.5
micron, 4.6 x 50 mm column heated at 60 C (Agilent Technologies # 865973-909).
Mobile phase is 0.1 % TFA in H O. GDNFv elutes as a single peak at 214 nm with a
retention time of 19-20 min by a linear acetonitrile gradient from 5 to 50% over 30 min at
a flow rate of 1 ml/min for 35 min.
Analytical size exclusion chromatography (SEC-HPLC). On TSK-GSW-XL ,
micron, 7.8 x 300 mm column (TOSOH BIOSEP #08540). Mobile phase: PBS +
350 mM NaCl, pH 7.4, at a flow rate of 0.5 ml/min for 35 min. GDNFv elutes as a single
peak at 214 nm with a retention time of ~16-17 min.
Analytical Cation Exchange Chromatography (CEX-HPLC). On Dionex, Propac
WCX-10, 4 x 250 mm column (Dionex #054993). Mobile phase is 20 mM sodium
Phospahte, 10% acetonitrile, pH 7. GDNFv elutes as a complex peak with a retention
time of 25-30 min by a linear salt gradient from 0.15 to 0.6 M NaCl over 45 min with a
flow rate of 1 ml/min for 52 min.
Chemical Stability Analysis (LC-MS) of Wild Type (full length bacterial GDNF) vs
Wild Type CHO GDNFv (N-terminus ∆31 truncated GDNF).
Wild type (full length bacterial GDNF) vs wild type CHO GDNFv (N-terminus
∆31 truncated GDNF) are stressed at 37 ºC for 4 weeks to identify amino acids that may
be associated with chemical instability.
Samples
1- WT E.coli full length GDNF at 4 °C for 4 weeks, 1.0 mg/mL
2- WT E.coli full length GDNF at 37 °C for 4 weeks, 1.0 mg/mL
3- WT CHO ∆31-GDNFv at 4 °C for 4 weeks, 1.0 mg/mL
4- WT CHO ∆31-GDNFv at 37 °C for 4 weeks, 1.0 mg/mL
Intact and Partially Molecular Analysis. A 10 μL aliquot of each sample ( solution is
mixed with 20 μL of water or 10 μL aliquot of each solution) is mixed with 40 μL of 100
mM tris-HCl buffer, pH8, 1.0 μL of 50 mg/mL DTT at ambient temperature for 30 min.
Each sample is submitted for LC/MS analysis.
Lys-C Digest. A 20 μL aliquot of each sample solution is lyophilized to dryness under
speed vacuum system and the material is then reconstituted in 0.5 μL of 50 mg/mL DTT
and 4.5 μL of 6 M guanidine-HCl, 0.5 M tris-HCl buffer, pH 8. The mixture is incubated
at 37 ⁰C for 30 minutes and each solution is then diluted with 93 μL of water and treated
with 2 μL of 0.2 mg/mL Lys-C (Wako) at 37 ⁰C for 2 hours. For CHO GDNFv, 30 μL of
the tryptic digest is treated with 0.5 μL of PNGase F at 37 ⁰C for 1 hour (to assess the
carbohydrate profile). The digest is acidified with 2 μL of 10% TFA in H O before
LC/MS analysis.
LC/MS Analysis. The sample solutions are analyzed by a Waters SYNAPT mass
spectrometry coupled with a Waters Acquity UPLC or a Water LCT premier mass
spectrometry coupled with a Waters 2795 HPLC.
Top-Down Analysis. The cleavage products for wild type GDNF are obtained by LC-MS
analysis for partially reduced GDNF. Multiple cleavage products are identified and
quantitative data for those cleavages are showed on Table 2. Several cleavages
(cleavages between N15/R16, N22/P23, N25/S26, and N38/R39) have similar
degradation pathways as deamidation through succinimide formation. For wild type
CHO ∆31-GDNFv, the first 31 amino acid residues are cleaved from the N-terminus.
Although CHO GDNFv has two potential N-glycosylation sites per chain, only one site is
N-glycosylated. Major glycans observed are di- or tri-antennary oligosaccharides with
different galactosylation. Interestedly, no significantly sialylated glycans are detected.
(Table 3)
Bottom-Up Analysis (Peptide Mapping). UV chromatograms of Lys-C digest of reduced
GDNF stability samples show that, with the exception of GDNF peptide 126-129, all the
expected peptides are detected. For CHO material, N-terminal peptides (before R32) are
not detected. Peptide 38-60 containing N49 is glycosylated and more than 95% of Asn49
is occupied. Peptide 85-96 containing N85 is not glycosylated. These results are
consistent with LC/MS analysis for reduced GDNF samples.
Overall, homo dimer for both wild type and CHO materials is the major
component. The minor component, which elutes early, is monomer. According to mass
spectroscopy analysis, GDNF Cys41 forms a disulfide bond with a free Cys residue for
the monomer. Relative percent for the monomer peaks is very low, and they are <1% for
CHO and <0.5% for the wild type by ultraviolet analysis. The monomer content is not
changed for the stressed materials.
The degradations, such as oxidation, deamidation and isomerization, are also
obtained from the peptide mapping. The results are shown in Table 4. Wild type full
length GDNF from E. coli. contains two Met residues, M(-1) and M6, and oxidation for
those sites are relatively low. GDNF does not contain any Trp residue. GDNF has eight
Asp residues for the full length monomer. The major deamidation sites are N25 and N38.
Since deamidation occurs much faster at high pH buffer, relative percentage for those
sites should be low when stressed in pH 5 or 6 buffer. One isomer peptide, 85-96, is
identified but it is not clear due to isomerization of Asp to Iso-Asp or racemization of
amino acid residue. It is well-known that high pH stress is generally racemization and
low pH stress is Asp isomerization. For wild type full length GDNF, several peptides
show the different masses for both the control (4 ºC) and stressed (37 ºC) samples. They
are most likely mis-incorporation during E. coli. biosynthesis.
Table 2. Relative Percent of GDNFs Cleavage.
WT- E. coli GDNF WT- E. coli GDNF CHO-∆31- GDNFv
GDNF Peptides
4 weeks, 4 ºC 4 weeks, 37 ºC 4 weeks, 37 ºC
Met + 1 – 134 90.9 57.6 NA
1-134 2.8 4.1 NA
2-134 2.5 4.2 NA
3-134 <0.5 1.5 NA
7 – 134 0.5 2.4 NA
16 – 134 <0.5 2.9 NA
Pyro E17, 17 - 134 <0.5 2.9 NA
18 – 134 0.6 2.0 NA
19 – 134 1.7 4.1 NA
-134 <0.5 3.8 NA
26 – 134 <0.5 2.7 NA
32 – 134 <0.5 2.9 97.3
39 – 134 <0.5 4.5 2.7
Table 3. CHO-∆31-GDNFv: Glycans at Glycosylation Site N49
Glycan Formula at N49 Relative Percent (%)
NeuAc HexNAc Hex Fc 4 ºC for 4weeks 37 ºC for 4 weeks
0 2 3 0 0.5 0.5
0 2 3 1 4.3 4.4
0 3 3 0 1.9 2.2
0 3 3 1 15.1 14.8
0 4 3 0 1.8 1.5
0 3 4 1 2.6 3.1
0 4 3 1 9.4 10.0
0 5 3 0 1.3 1.5
0 4 4 1 3.4 3.5
0 5 3 1 6.6 7.0
0 4 5 1 6.3 6.5
0 5 4 1 3.4 3.7
0 6 3 1 1.3 1.4
0 5 5 1 4.0 4.5
0 5 6 0 3.4 3.1
0 6 4 1 1.5 1.5
0 5 6 1 22.5 20.9
0 6 7 0 0.7 0.6
0 6 7 1 5.1 4.6
0 7 8 1 0.5 0.8
Aglycosylation at N49 4.3 4.1
Table 4. LC-MS Peptide Mapping.
Relative Percent (%)
Residue/Peptides
WT- E. coli GDNF CHO-∆31-GDNFv
4 ºC, 4 weeks 37 ºC, 4 weeks 4 ºC, 4 weeks 37 ºC, 4 weeks
Oxidation
Met(-1) 1.4 2.5 na na
Met6 6.4 11.2
na na
Deamidation
N15/N25, Major N25 2.8 61.5 na na
N38 1.9 20.3 6.7 27.6
N89 <0.5 4.0 1.2 3.5
Isomerization
GDNF Peptide 85-96 <0.5 14.4 3.6 17.7
Not available.
These data indicate that the ∆31-N-terminus truncated GDNF variant produced in CHO
cells has improved chemical stability due to the deletion of the first 31 amino acid
residues that include significant oxidation and deamidation hot spots, as compared with
the E. coli-produced full length wild type mature human GDNF when stressed for 4
weeks at 37 ºC. Further, as shown in Table 5, significant improvement in the
biophysical and biochemical properties of two mutated ∆31-N-terminus truncated GDNF
variants (N38Q and D95E, respectively) was observed after mutation as compared to
either the full length wild type E. coli GDNF or the ∆31-N-terminus truncated GDNF
variant before mutation.
Table 5. Improved Biophysical and Biochemical Properties of GDNF Variants vs Wild
Type GDNF After 4 Weeks Incubation at 37 °C Relative to the 4°C samples
CHO-∆31- CHO-∆31-
WT- E. coli
CHO-∆31-
N38Q- N38Q-K84A-
GDNF
GDNFv
D95E- R88K-R90K-
(SEQ ID
(SEQ ID
GDNFv D95E-
NO: 8)
NO: 3)
(SEQ ID GDNFv
NO: 9) (SEQ ID NO:
° ° ° ° ° ° ° °
4 C 37 C 4 C 37 C 4 C 37 C 4 C 37 C
A- High Molecular Weight
Aggregate % (SEC)
a- 0.5 mg/ml na na 1.2% 2.7% 0.7% 1.4% 0.9% 1.7%
b- 0.1 mg/ml na na <2% <2% <2% <2% <2% <2%
d- 15 mg/ml na na 0.68% na 0.43% na 0.47% na
e- 15 mg/ml (3freeze/thaw) na na 0.66% na 0.41% na 0.43% na
B- Chemical Degradation (RP,
% of non main peak)
a- 0.5 mg/ml na na 4.3% 5.7% 0.3% 1.5% 0% 1.9%
b- 0.1 mg/ml na na na >90% na >90% na >90%
C- Chemical Stability and
Modification (CEX, % of main
peak)
a- 0.5 mg/ml 8% 82.3% 30% 86% 57% 90% 62%
b- 0.1 mg/ml na na na <30% 55% na 53%
D- N-terminal Clipping
(LC-MS mature GDNF peptide
sequence, 1 mg/ml)
a-Met134 91% 58% na na na na na na
b- 1-134 2.8% 4.1% na na na na na na
c- 32-134 <0.5% 3.0 % 98.2% 92.8% 99.6% 96.0% 98.4% 94.9%
d- 33-134 na na 1.8% 3.3% 0.4% 2.1% 1.5% 3.2%
e134 na na 0.0% 1.8% 0.0% 1.9% 0.1% 1.9%
f134 na na 0.0% 2.1% 0.0% 0.0% 0.0% 0.0%
E- Oxidation(LC-MS)
a- Met (-1) 1.4% 2.5% na na na na na na
b- Met (6) 6.4% 11.2% na na na na na na
F- Deamidation (LC-MS)
a- N15/25 2.8% 61.5% na na na na na na
b- N38/Q38 1.9% 20.3% 3.2% 25.9% 0.7% 0.7% 0.5% 0.6%
c- N89/N85 <0.5% 4% 1.3% 2.2% 1.0% 1.7% 1.2% 1.9%
G- Isomerization/Racemization
(LC-MS)
a- peptide 85-96 <0.5% 14.4% 0.9% 12.0% 0.0% 0.2% 0.1% 0.8%
H- Glycosylation (LC-MS)
a- N49 Occupancy na na 99.3% 99.3% 99.6% 99.7% 98.1% 97.9%
b- Sialic Acid (mole/glycan) na na 0.9 0.9 0.6 0.6 1.4 1.4
c- Di-antennary na na 7.8% 7% 10.8% 10.5% 9.8% 9.2%
d- Tri-antennary na na 54.9% 54.5% 49.5% 50.9% 55.9% 55.8%
e- Tetra-antennary na na 37.2% 38.5% 38.5% 37.5% 33.1% 33.7%
Not available (na)
Example 3
In vitro Binding Activities
The following assays demonstrate that certain variants of human GDNF reduce heparin
binding while maintaining GFRα1 receptor binding to provide a variety of differential
heparin and receptor binding characteristics.
• Binding Kinetics of GDNFv to GFRs on Biacore
GDNF variants (GDNFv: N-terminus-∆31-truncated) may be expressed in E.coli
(bacterial) or mammalian cells (CHO cells or HEK293 EBNA cells) and purified as
described in Example 1. The primary sequences of the variants remains the same
regardless which expression system is used.
A Biacore® 2000 instrument is used to measure the binding kinetics of GDNFv to
human and rat GDNF family receptors (GFRα1 and GFRα2). Measurements are
performed at 25°C. Samples are dissolved in HBS-EP buffer (150 mM sodium chloride,
3 mM EDTA, 0.005% (w/v) surfactant P-20, pH 7.4). Protein A, Staphylococcus aureus
is immobilized on flow cells 1 to 4 of a CM4 sensor chip (GE Healthcare #BR39)
at a level of ~200 response units (RUs) using amine coupling chemistry to capture GFR
Fc chimera (Recombinant Human GFRα-1/GDNF Rα-1 Fc Chimera; Recombinant
Human GFRα-2/GDNF Rα-2 Fc Chimera; Recombinant Rat GFRα-1/GDNF Rα-1 Fc
Chimera; Recombinant Mouse GFRα-2/GDNF Rα-2 Fc Chimera).
Binding is evaluated using multiple cycles. Each cycle consists of the following
steps: 1) injection of about 10 µL of GFR at a concentration of ~1.0 µg/mL and a flow
rate of 10 µL/min., aiming at a capture of 120-150 RUs; 2) injection of 250 µL of GDNFv
at a flow rate of 50 µL/min., in a final concentration rage between 10 nM and 0.04 nM
followed by 20 min. for dissociation; and 3) regeneration using about 30 µL of 10 mM
glycine hydrochloride, pH 1.5. Association and dissociation rates for each cycle are
evaluated using a “1:1 (Langmuir) binding” model in the BIAevaluation software, version
4.1.
The results are shown in Tables 6-8 below.
Table 6. GDNFv: Binding Kinetics and Affinity to Human GFRα-1
-1 -1 -1
GDNFv k (M s ) k (s ) K (pM)
On Off D
E.Coli-WT-GDNF (SEQ ID
6 -4
(6.0 ± 2.3) x 10 (3.5 ± 0.8) x 10 64 ± 23
NO:3)
E.Coli-∆31-GDNF (SEQ ID
6 -4
(4.2 ± 1.3) x 10 (1.7 ± 0.7) x 10
44 ± 30
NO:8)
E.coli-∆31-N38Q-D95E-GDNF
6 -4
(3.9 ± 1.3) x 10 (1.6 ± 0.3) x 10
47 ± 25
(SEQ ID NO:9)
E.Coli-∆31-N38Q-K84A-R88K4
R90K-D95E-GDNF (SEQ ID (5.0 ± 1.8) x 10 (1.6 ± 0.2) x 10
± 18
NO:12)
CHO-∆31-GDNF (SEQ ID
6 -4
(3.8 ± 1.5) x 10 (0.9 ± 0.1 x 10 29 ± 17
NO:8)
CHO-∆31-N38Q-D95E-GDNF
6 -4
(4.5 ± 2.1) x 10 (1.1 ± 0.2) x 10 30 ± 14
(SEQ ID NO:9)
CHO-∆31-N38Q-K84A-R88K4
R90K-D95E-GDNF (SEQ ID (6.2 ± 3.2) x 10 (1.4 ± 0.4) x 10
29 ± 15
NO:12)
Determined in the presence of 400 mM NaCl.
Table 7. GDNFv: Binding Kinetics and Affinity to Human GFRα-2.
-1 -1 -1
GDNFv k (M s ) k (s ) K (pM)
On Off D
E.Coli-WT-GDNF (SEQ ID
6 -4
2.4 x 10 2.6 x 10 100
NO:3)
CHO-∆31-GDNF (SEQ ID
6 -4
.3 x 10 2.5 x 10 47
NO:8)
CHO-∆31-N38Q-D95E-GDNF
6 -4
7.6 x 10 3.5 x 10 47
(SEQ ID NO:9)
CHO-∆31-N38Q- K84A-R88K4
R90K-D95E –GDNF (SEQ ID 9.6 x 10 4.2 x 10 44
NO:12)
Table 8. Binding Kinetics and Affinity of GDNFv to Rat GFRα-1.
-1 -1 -1
GDNFv k (M s ) k (s ) K (pM)
On Off D
CHO-∆31-GDNF (SEQ ID
6 -4
.6 x 10 2.4 x 10 44
NO:8)
CHO-∆31-N38Q-D95E-GDNF
6 -4
9.4 x 10 1.9 x 10 20
(SEQ ID NO:9)
CHO-∆31-N38Q- K84A-R88K4
R90K-D95E–GDNF(SEQ ID 9.9 x 10 2.1 x 10 21
NO:12)
• Binding of Human GDNF Variants to GFRα1 using ELISA
GDNF wild type and variants are tested in an ELISA assay, in which binding of
the GDNF proteins to the plate-bound receptor (GFRα1) is measured. A “no GDNF”
condition and/or an “irrelevant protein” condition are used as negative controls.
Each well of a 96-well plate (Greiner 655081 Immunobind ELISA plates) is
coated with 70 µl of human GFRα1 (recombinant human GFRα1-Fc chimera, carrier-
free) at 1µg/ml in carbonate buffer, pH 9.6. If an irrelevant receptor is coated, it is an
irrelevant Fc chimera and is coated at the same concentration as GFRα1. The plates are
sealed and incubated at 4°C overnight. The wells are aspirated and washed twice with
washing buffer (20 mM Tris (hydroxymethyl) aminomethane, pH 7.4, 0.15 M NaCl, 0.1%
Tween-20), using an automatic plate washer. The plates are blocked with 200 µl blocking
buffer per well (3% Carnation Instant milk in the above washing buffer) for at least 1
hour at room temperature. Plates are washed twice with washing buffer.
GDNF proteins are serially diluted into blocking buffer at an appropriate
concentration range, typically beginning at 5 µg/ml and serially diluting 1:10. A no
GDNF control is used, which consists of blocking buffer alone. 50 µl of each GDNF
solution is added to the GFRα1 coated wells in triplicate. The plates are incubated for 1.5
hours at room temperature. The wells are then washed 3 times with washing buffer.
A 50 µl aliquot of biotinylated anti-human GDNF antibody (R&D Systems,
biotinylated goat anti-human GDNF polyclonal antibody, catalog # BAF212) diluted to a
concentration of 1 µg/ml in blocking buffer, is added to each well and incubated for 45
minutes at room temperature. The wells are then washed 3 times with washing buffer.
A 50 µl aliquot of horseradish peroxidase-conjugated streptavidin (Jackson
ImmunoResearch, catalog # 016084), diluted 1:1000 in blocking buffer, is added to
each well and incubated for 20-30 minutes at room temperature. Alternatively, a 1:2000
dilution can be used, with an incubation time of 30-90 minutes. The wells are then
washed 3 times with washing buffer. 50 µl of chromogenic substrate (i.e., OPD
substrate) is added to each well and allowed to develop at room temperature for 2-3
minutes. The reaction is stopped by adding 100 µl of 1N HCl to each well. The
absorbance of the wells is read at 490 nm on a Molecular Devices SpectraMax250 plate
reader. The average absorbance for the triplicate wells for each condition are determined,
and the resulting values are processed for EC calculation with Graph Pad Prism
software to provide a 95% confidence range. Those ranges are summarized in Table 9
below.
• Binding of Human GDNF Variants to Heparin using ELISA
GDNF wild type and variants are tested in an ELISA assay, in which binding of
the GDNF proteins to plate-bound heparin is measured. A “no GDNF” condition is used
as a negative control.
Each well of a 96-well Heparin Binding plate (BD BioSciences Heparin Binding
Plates, catalog # 354676) is coated with 70 µl of heparin ((mixed molecular weight
heparin from Sigma, Heparin Sodium Salt from Porcine Intestinal Mucosa, catalog # H-
3149) at 5 µg/ml in PBS. The plates are sealed and incubated at room temperature
overnight, protected from light. The wells are aspirated and washed three times with
washing buffer, using an automatic plate washer. The plates are blocked with 200 µl
blocking buffer per well for 90-120 minutes at 37°C (plates are sealed during this
incubation). Plates are washed twice with washing buffer.
GDNF proteins are serially diluted into blocking buffer at an appropriate
concentration range, typically beginning at 5 µg/ml and serially diluting 1:10. A “no
GDNF” control, consisting of blocking buffer alone, is used. A 50 µl aliquot of each
GDNF solution is added to the heparin coated wells in triplicate. The plates are incubated
for 1.5-2 hours at room temperature. The wells are then washed 3 times with washing
buffer.
A 50 µl aliquot of biotinylated anti-human GDNF antibody, diluted to a
concentration of 1 µg/ml in blocking buffer, is added to each well and incubated for 45
minutes to 1 hour at room temperature. The wells are then washed 3 times with washing
buffer.
A 50 µl aliquot of horseradish peroxidase-conjugated streptavidin, diluted 1:1000
in blocking buffer, is added to each well and incubated for 20-30 minutes at room
temperature. Alternatively, a 1:2000 dilution can be used, with an incubation time of 30-
90 minutes. The wells are then washed 3 times with washing buffer. A 50 µl aliquot of
chromogenic substrate (i.e., OPD substrate) is added to each well and allowed to develop
at room temperature for 2-3 minutes. The reaction is stopped by adding 100 µl of 1N
HCl to each well. The absorbance of the wells is read at 490 nm on a plate reader. The
average absorbance for the triplicate wells for each condition are determined, and the
resulting values are processed for EC calculation with Graph Pad Prism software to
provide a 95% confidence range. Those ranges are summarized in Table 9 below.
Table 9
GFRα1 binding,
# of Heparin binding,
EC 95% # of
Variants Expts. EC 95%
confidence Expts. (n)
(n) confidence range
range
E.Coli-WT-GDNF
8 0.3 - 0.4 nM 10 0.2 - 0.4 nM
(SEQ ID NO:3)
CHO ∆31 GDNF
14 0.3 - 0.6 nM 16 2.0 - 5.0 nM
(SEQ ID NO:8)
CHO ∆31-N38Q-
D95E GDNF (SEQ 4 0.3 – 1.9 nM 3 19.8 – 41.3 nM
ID NO:9)
CHO ∆31-N38Q-
Could not
K84A-R88K- Could not determine;
determine; no
R90K-D95E 5 5 no max plateau for 4
max plateau for 4
GDNF (SEQ ID of 5 expts
of 5 expts
NO:12)
CHO ∆31-N38Q-
K84A-R88K-
Little to no
R90K-D95E - Little to no binding
1 binding seen by 1
K125E-R130E seen by this ELISA
this ELISA
GDNF (SEQ ID
NO:15)
*2 individual
experiments are done,
no composite
These data show that the deletion of the N-terminal 31 amino acids (variant named “CHO
∆31 GDNF”) from the wild type GDNF (named “WT E. coli GDNF”) can reduce heparin
binding significantly (approximately 10-fold) while maintaining GFRα1 receptor binding,
and these data further indicate that a variety of differential heparin and receptor binding
characteristics can be achieved through additional variants of human GDNF.
Example 4
In vitro Activities
• NS-1 Neurite Outgrowth Assay
GDNF activity for neuronal differentiation is assessed using rat Neuroscreen-1
cells (PC12 subclone). The cells are maintained in F-12K basal medium, 12.5% heat
inactivated horse serum, 2.5% heat inactivated fetal bovine serum (FBS), 1X
GlutaMAX (Invitrogen, Cat.# 35050061), and 1X Anti-anti (Invitrogen, Cat.#15240) at
37 °C, 95% humidity in collagen coated flasks. To measure neurite outgrowth, the
Neuroscreen-1 cells are seeded into Collagen I 96-well plates at 2200 cells per well in
growth medium using only the interior 60 wells. After 24 hours of cell attachment, the
medium is removed and new growth medium containing GFRα1-Fc at 1µg/ml plus
GDNF diluted in an 8 point dilution series is added to the plate in either triplicate wells,
or six wells per concentration. Medium plus 1µg/ml GFRα1-Fc is included as a negative
control, and medium plus 25 ng/ml neurite growth factor is included as a positive control
for cell response in the assay. The plates are incubated for 96 hours at 37°C, 95%
humidity and then fixed by adding 45µl fixative solution to each well and incubating at
room temperature for 1 hour. The plates are washed twice with 1X wash buffer from
Neurite Outgrowth Hit Kit (Cellomics, Cat.#K071) and then washed twice with
1X buffer from the kit. The cells are immuno-stained with the neurite outgrowth reagents
from the kit according to manufacturer’s instructions. The plates are loaded onto
Arrayscan Instrument and analyzed using Arrayscan software and Neuronal Profiling
algorithm from Cellomics. Data generated by the algorithm is processed for EC50
calculation with Graph Pad Prism software.
Multiple variants are tested for activity in neuronal differentiation and the
observed EC50s for each variant are listed in Table 10A.
Table 10A. GDNFv: NS-1 Neurite Outgrowth
GDNFv Repeats
(95% confidence range)
E.Coli-WT-GDNF (SEQ ID
3 33 - 200 pM
NO:3)
CHO-∆31-GDNF (SEQ ID
17 42 - 82 pM
NO:8)
CHO-∆31-N38Q-D95E-GDNF
47 - 227 pM
(SEQ ID NO:9)
CHO-∆31-N38Q-K84A-R88K-
R90K-D95E-GDNF (SEQ ID 5 52 – 384 pM
NO:12)
CHO-∆31-N38Q-K84A-R88K-
R90K-D95E-K125E-R130E- 2 nd
GDNF (SEQ ID NO:15)
Not determined due to either low potency or failure to reach maximum plateau.
All GDNF samples tested here have activity in the neurite outgrowth assay, to varying
degrees. The dose curves for the ∆31-N38Q-K84A-R88K-R90K-D95E-K125E-R130E
variant do not reach a plateau at a maximum dose in the two experiments performed, so
an EC50 could not be calculated. The EC 95% confidence intervals for the other four
GDNF variants overlap in range, demonstrating similar levels of activity in this assay.
• C-Ret Receptor Phosphorylation
The c-Ret receptor phosphorylation assay can be used to demonstrate the induction of
cRet receptor phosphorylation at position Y1016. GDNF activity for c-Ret receptor
phosphorylation is assessed in cells from the human neuroblastoma cell line SH-SY5Y
(ATCC) which have been stably transfected to over-express human c-Ret. The cells are
maintained in Dulbecco's modified Eagle medium (DMEM), 10% FBS, 3µg/ml
Blasticidin. For c-Ret phosphorylation, the cells are seeded at 5 x 10 per well into 24-
well collagen coated plates in growth medium without Blasticidin and allowed to attach
overnight. The medium is changed to low glucose DMEM + 0.25% BSA (bovine serum
albumin) for 24 hours. Starvation medium is removed, and the cells are treated with
GDNF in no glucose DMEM, 0.25% BSA, 1µg/ml GFRα1-Fc for 30 minutes at 37°C.
Each GDNF variant is tested at multiple concentrations. The treatment medium is
removed, and the cells are scraped from the plate surface in ice-cold lysis buffer of M-Per
Extraction reagent + Protease Inhibitor cocktail, Phosphatase Inhibitor 1, Phosphatase
Inhibitor cocktail 2, and Phosphphatase Inhibitor cocktail 3 (Sigma ). The cell
suspensions are vortexed to complete lysis, centrifuged at 14,000 x g to pellet cell debris,
and the supernatant is quantified for protein concentration using the bicinchoninic acid
(BCA) assay reagents. For each GDNF lysate, 10µg protein is separated by 4-12%
NuPAGE® Novex® Bis-Tris Gels (Invitrogen, Cat.# NP0322) and transferred PVDF
blots. Tyrosine 1016 phospho-Ret is detected with a rabbit polyclonal antibody and goat-
anti-rabbit-HRP antibody; and c-Ret is detected with a mouse monoclonal antibody and a
goat-anti-mouse-HRP antibody. The blots are developed with the Supersignal West
Pico (Thermo Scientific, Cat.# 34081) reagents and exposed to x-ray film.
Five GDNF variants (WT E.coli GDNF, CHO ∆31 GDNF, CHO ∆31-N38Q-D95E
GDNF, CHO ∆31-N38Q-K84A-R88K-R90K-D95E GDNF, and CHO ∆31-N38Q-K84A-
R88K-R90K-D95E-K125E-R130E GDNF) are tested in no glucose DMEM, 0.25% BSA
medium + 1µg/ml GFRα1-Fc for c-Ret phosphorylation activity at four concentrations of
0.8, 2.0, 4.0, 10, 20, 50 and 100 ng/ml. Medium alone, medium + 1µg/ml GFRα1-Fc, and
medium + 100ng/ml CHO ∆31 GDNF are also tested as negative controls. Each of the
five GDNF variants induce c-Ret phosphorylation with an EC of 8-15ng/ml. These
data demonstrate that all five GDNF variants induce c-Ret phosphorylation at Y1016 in a
dose dependent manner.
As summarized in Table 10B, the engineered ∆31-N-terminus truncated GDNF
variants that showed significant improvement in biophysical and biochemical properties
(Tables 5, 6, 9, and 10A) maintained optimized biological properties, e.g.,comparable
GFRα1 receptor binding, decreased heparin binding, and comparable neurite outgrowth,
after 4 weeks of incubation at 37 °C.
Table 10B: Bioactivity Comparison of WT- E. coli GDNF and ∆31-N-terminus truncated
GDNF variants After 4 Weeks Incubation at 37 °C Relative to the 4°C samples
CHO-∆31-
WT- E. coli
CHO-∆31- CHO-∆31-N38Q-
N38Q-D95E-
GDNF
GDNFv K84A-R88K-R90K-
GDNFv
(SEQ ID D95E-GDNFv
(SEQ ID
(SEQ ID NO:
NO: 8) (SEQ ID NO: 12)
NO: 3)
° ° ° ° ° ° ° °
4 C 37 C 4 C 37 C 4 C 37 C 4 C 37 C
64 ±
GFRα-1 (Biacore, K , pM)
nc 29 ± 17 nc 30 ± 14 nc 29 ± 14 nc
GFRα-1 (ELISA, EC ,
0.4 nc 0.6 nc 0.8 nc nd nd
Heparin (ELISA, EC , nM)
0.3 0.4 2.7 5.1 18.0 nc nd nd
Neurite Outgrowth (EC
33-200 nc 42-82 nc 47-227 nc 52-384 na
range, pM)
Not available (na); Not determined (nd); and No change (nc)
Example 5
GDNF Variant Activity in DA Turnover Assays
Male Sprague-Dawley rats are anaesthetized using isoflurane (3% in O ). The
head is shaved and sterilized with iodine solution before the animal is positioned on a
stereotaxic frame with temperature-controlled mat. The eyes are protected with
ophthalmic gel and anaesthesia is maintained using isoflurane (1-2% in O ).
A midline incision is made on the animal’s head, the scalp and underlying tissue reflected
and the skull dried to visualize bregma. Coordinates for the caudate nucleus are
measured from bregma and dural surface for infusion of GDNF. A 28 gauge infusion
cannula is slowly lowered to this position, and the infusion commences 1 minute later
using a pump. A 2 µl bolus of the test GDNF is infused into the left hemisphere over 4
minutes at 0.5 µl/min, and the cannula remains in place for a further 3 minutes once the
infusion ceases. Once the cannula has been removed the incision site is closed, a post-
operative analgesic administered and the animal allowed to recover in a temperature-
controlled cage before transfer to a home cage. Animals are checked post-operatively in
accordance with local ethical guidelines. At an appropriate interval following the
infusion, the animal is sacrificed, the brain removed and the caudate nuclei accurately
dissected, weighed and frozen pending HPLC analysis of dopamine and metabolites.
The frozen tissue is allowed to thaw quickly and is homogenized in 0.5ml of
homogenization buffer (0.1 M perchloric acid (PCA), 0.1 mM Ethylenediaminetetraacetic
acid (EDTA), 2.5mg/L ascorbic acid) before centrifugation at 20,000g for 15 minutes.
The supernatant is removed and filtered through a syringeless filtration device. Analysis
of dopamine (DA), dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA)
is carried out using HPLC coupled to electrochemical detection. A 20µl aliquot of each
sample is injected and quantified against an external calibration curve (LC4C, BAS,
USA). Mobile phase consists of 100 mM NaH PO , 100 mM H PO , 2 mM OSA, 1mM
2 4 3 4
EDTA, 13% Methanol (MeOH), pH2.8 using a Hypersil BDS (Base Deactivated Silica)
(Thermo Scientific, Cat.# 28105) 150 x 3.0 mm C18 3µ particle column at 40°C. Data
are collected using Empower chromatography software. A 4-parameter logistic fit is
performed on all data prior to expression as ng/g wet weight tissue. The dopamine
turnover measure is expressed as (DOPAC+HVA)/DA and comparisons performed with
left hemisphere (treated) versus right hemisphere (intact).
Table 11
Variant Dopamine turnover Dopamine turnover
Treated (left) Intact (right)
E. coli-WT GDNF (SEQ ID NO:3) 0.25 ± 0.025 0.15 ± 0.008
CHO- ∆ 31-GDNF (SEQ ID NO:8) 0.25 ± 0.016 0.14 ± 0.006
CHO-∆31-N38Q-D95E-GDNF (SEQ
0.25±0.018 0.13±0.007
ID NO:9)
CHO-∆31-N38Q-K84A-R88K-
R90K-D95E –GDNF (SEQ ID NO: 0.20±0.015 0.13±0.012
CHO-∆31-N38Q-K84A-R88K-
R90K-D95E-K125E-R130E-GDNF 0.19±0.021 0.14 ± 0.011
(SEQ ID NO:15)
Values are mean ± s.e.m. n=5 per group
** p< 0.01 or *** p<0.001 vs intact side
The data demonstrate that each of the GDNF variants named in Table 11
significantly increase dopamine turnover in the treated hemisphere, as compared to the
intact hemisphere.
Example 6
In vivo Assays
• 6-Hudroxy Dopamine (6-OHDA)-induced Retrograde Lesion Model
Male Sprague-Dawley rats are anaesthetized using isoflurane (3% in O2). The
head is shaved and sterilised with iodine solution before the animal is positioned on a
stereotaxic frame with temperature-controlled mat. The eyes are protected with
ophthalmic gel and anaesthesia is maintained using isoflurane (1-2% in O2).
A midline incision is made on the animal’s head, the scalp and underlying tissue reflected
and the skull dried to visualize bregma. Coordinates for the caudate nucleus are
measured from bregma and dural surface for infusion of 10ug 6-Hydroxydopamine (6-
OHDA). A 28 gauge infusion cannula is slowly lowered to this position and the infusion
commences 1 minute later. A 2 µl bolus of the 6-OHDA is infused into the left
hemisphere over 4 minutes at 0.5µl/min and the cannula remains in place for a further 3
minutes once the infusion ceases.
At 30 minutes following the 6-OHDA infusion the test GDNF is infused using the
same protocol. Coordinates for the GDNF infusion are Anterior-Posterior +1.0, LM -2.5,
DV -4.5mm from bregma and dural surface as before.
Once the cannula has been removed the incision site is closed, a post-operative analgesic
administered and the animal allowed to recover in a temperature-controlled cage before
transfer to a home cage. Animals are checked post-operatively in accordance with local
ethical guidelines. At an appropriate interval following the infusion the animal is
sacrificed, the brain removed and the caudate nuclei and substantia nigra accurately
dissected, weighed and frozen pending HPLC analysis of dopamine and metabolites.
The frozen tissue is allowed to thaw quickly and is homogenized in 0.5ml of
homogenization buffer (0.1M PCA, 0.1mM EDTA, 2.5 mg/L ascorbic acid) before
centrifugation at 20,000 xg for 15 minutes. The supernatant is removed and filtered
through a syringeless filtration device. Analysis of dopamine (DA), DOPAC and HVA is
carried out using HPLC coupled to electrochemical detection. A 20 µl aliquot of each
sample is injected and quantified against an external calibration curve. Mobile phase
consists of 100 mM NaH PO , 100 mM H PO , 2mM OSA, 1 mM EDTA, 13% MeOH,
2 4 3 4
pH 2.8 using a BDS Hypersil 150 x 3.0 mm C18 3µ particle column at 40 °C. Data is
collected using Empower chromatography software. A 4-parameter logistic fit is
performed on all data prior to expression as ng/g wet weight tissue. Comparisons are
performed with left hemisphere (treated) versus right hemisphere (intact).
Table 12: Caudate nucleus
Variant Dopamine (ng/g) Dopamine (ng/g) % depletion
Treated (left) Intact (right)
Vehicle 2617.59 ± 526.91
81.35
14033.40 ± 408.75
E.coli-WT-
GDNF (SEQ
81.71
2707.72 ± 725.92 14805.36 ± 536.71
ID NO:3)
CHO-∆31-
GDNF (SEQ
86.00
2023.86 ± 818.03 14456.09 ± 691.53
ID NO:8)
CHO-∆31-
N38Q-D95E-
82.14
2676.57 ± 558.37 14986.15 ± 931.85
GDNF (SEQ
ID NO:9)
CHO-∆31-
N38Q-K84A-
R88K-R90K-
13730.74 ± 1238.50 77.33
3112.14 ± 717.45
D95E –GDNF
(SEQ ID NO:
Values are mean ± s.e.m. n=8 per group
*** p<0.001 vs intact side
Table 13: Substantia Nigra
Variant Dopamine (ng/g) Dopamine (ng/g) % depletion
Treated (left) Intact (right)
Vehicle
571.33 ± 90.65 990.73 ± 134.48 42.33
E.Coli-WT-
** #
GDNF (SEQ
836.51 ± 97.15 1167.38 ± 62.07 28.34
ID NO: 3)
CHO-∆31-
** #
GDNF (SEQ
856.48 ± 75.45 1160.82 ± 100.56 26.22
ID NO: 8)
CHO-∆31-
N38Q-D95E-
* #
903.68 ± 52.60 1152.24 ± 115.61 21.57
GDNF (SEQ
ID NO: 9)
CHO-∆31-
N38Q-K84A-
R88K-R90K-
970.06 ± 108.05 1174.45 ± 134.94 17.40
D95E –GDNF
(SEQ ID NO:
Values are mean ± s.e.m. n=8 per group
*p<0.05, ** p< 0.01 or *** p<0.001 vs intact side
# p<0.05, ## p<0.01 vs vehicle (treated side)
Administration of 6-OHDA into the caudate nucleus results in a significant decrease
in dopamine levels in the treated side compared to the intact side (Table 12). A
significant deficit is also observed in the substantia nigra (Table 13), which is prevented
by administration of GDNF. All variants of GDNF tested here are significantly different
from vehicle, comparing treated sides.
• Acute Biodistribution in Rat Brain
Male Sprague-Dawley rats are anaesthetized using isoflurane (3% in O ). The head is
shaved and sterilised with iodine solution before the animal is positioned on a stereotaxic
frame with temperature-controlled mat. The eyes are protected with ophthalmic gel and
anaesthesia is maintained using isoflurane (1-2% in O ).
A midline incision is made on the animal’s head, the scalp and underlying tissue are
reflected and the skull is dried to visualize bregma. Coordinates for the caudate nucleus
are measured from bregma and dural surface for infusion of GDNF (Anterior-Posterior +
0.5, Lateral Medial -3.0, DorsalVentral -5.5 mm). A 30 gauge infusion cannula is slowly
lowered to this position, and the infusion commences 1 minute later (using a pump). A 2
µl bolus of the test GDNF is infused into the left hemisphere over 4 minutes at 0.5 µl/min,
and the cannula remains in place for a further 3 minutes once the infusion ceases. Once
the cannula has been removed the incision site is closed, a post-operative analgesic is
administered, then the animal is allowed to recover in a temperature-controlled cage. At
an appropriate interval following the infusion, the animal is sacrificed and the brain
removed and frozen pending cryosectioning for immunohistochemistry.
• GDNF Immunohistochemistry (IHC) in Rat Brain
Biodistribution of infused GDNF is tested in an immunohistochemistry assay, in
which binding of the antibody to the infused antigen (GDNF and GDNF variants) is
measured in rat brains. An isotype control antibody is used as a negative control.
Cryosectioning the frozen rat brains begins with trimming the cerebellum while
inside a cryostat at -20 degrees C, using a rat brain matrix to make a flat surface. Optimal
Cutting Temperature (OCT, Sakura or other similar vendors) is placed on a cooled
cryostat specimen chuck. As the OCT begins to freeze, the flat caudal surface of the rat
brain is placed on the specimen chuck using -20 degrees C cooled forceps, so that the
OCT tacks the brain in place with the rostral-most brain facing away from the specimen
chuck. The specimen chuck is placed in the object holder and tighted. After a microtome
blade has been inserted into the knife holder, the trimming function on the cryostat is used
to discard the olfactory bulbs as well as the cerebrum, rostral to the infusion track. 8um
thick sections are taken at 300 µm intervals and placed on positively charged glass slides.
Two or three adjacent interval sections are placed on each glass slide for each rat brain.
Slides are then placed into 4% paraformaldehyde at room temperature for 20 minutes and
rinsed in tris-buffered saline tween-20 (TBST) washing buffer. Using a staining solution
at room temperature, the slides are incubated for 10 minutes with Dual endogenous
enzyme block, rinsed with TBST washing buffer, incubated for 15 minutes each of
Avidin and Biotin block, washed with TBST washing buffer, blocked with Protein block
for 60 minutes and blown off the slide using an air knife. Biotinylated anti-human GDNF
or a biotinylated goat IgG is diluted in Antibody Diluent with background reducing
agents to 2 µg/ml and incubated on the slide for 60 minutes, then rinsed with TBST
washing buffer 3 times. The slides are incubated with labelled streptavidin biotin 2
(LSAB2) (Dako, Cat.# K0609) for 10 minutes and rinsed with TBST washing buffer. The
slides are incubated with DAB+ (2 drops of DAB in DAB diluent for 5 minutes, then
rinsed with TBST washing buffer, followed by a rinse with distilled water. After slides
are removed from the autostainer, they are counterstained with Hematoxylin and
coverslipped using Cytoseal XYL (Stephens Scientific, Cat. # 8312-4). Slides are
allowed to dry and then analyzed using Aperio XT to quantify biodistribution.
• Quantification of Biodistribution of GDNF in Rat Brain
Images of the slides are acquired at the 20X magnification setting on an Aperio
ScanScope XT (running v10.00.00.1805 of the Controller software). Meta data about the
slides is stored in Aperio’s web-based software, Spectrum (v10.0.1346.1806).
Each brain section is manually outlined using Aperio’s image viewer software,
ImageScope (v10.0.36.1805). For the first study, the whole brain section with the least
amount of visible sectioning artifact is outlined. For the second study, the whole brain
section closest to the slide label is outlined. Each outlined region is analyzed using
Aperio’s “Positive Pixel Count” algorithm (v9) [with all the parameters kept at their
default settings, except Image Zoom = .01 and Intensity Threshold WEAK (Upper Limit)
= 235].
The GDNF distribution area in mm for each rat is computed by summing the
positive and strong positive areas output from the positive pixel algorithm. A paired
Student’s t-test is used to determine statistical significance.
Table 14. GDNFv: Rat Brain Biodistribution
Average Area of Distribution
GDNFv
(mm )
7.05 ± 2.92 Experiment 1
E.Coli-WT-GDNF (SEQ
9.16 ± 4.19 Experiment 2
ID NO: 3)
16.07 ± 5.69* Experiment 1
CHO-∆31-GDNF (SEQ
.88 ± 6.56** Experiment 2
ID NO: 8)
CHO-∆31-N38Q-D95E-
17.91 ± 1.47** Experiment 2
GDNF (SEQ ID NO: 9)
CHO-∆31-N38Q-K84A-
R88K-R90K-D95E- 20.86 ± 3.54** Experiment 2
GDNF (SEQ ID NO: 12)
Vehicle (PBS, negative
0.41 ± 0.25 Experiment 1
control)
IgG (negative control)
0.01 ± 0.03 Experiment 1
*For ∆ 31, p<0.003 with respect to vehicle, IgG and E.coli-WT-GDNF,
**Statistically significant with respect to E.coliWT-GDNF, p<0.05
The ELISA data on heparin binding (Table 9) demonstrate that modifications to
the wild type GDNF can reduce heparin binding compared to E.coli-WT GDNF. These
data, together with the biodistribution data shown above in Table 14, confirm that
variants that decrease heparin binding can result in an increase in biodistribution in the rat
brain. N38Q-D95E and N38Q-K84A-R88K-R90K-D95E variants listed in the above table
have increased biodistribution compared to E.coli-WT-GDNF.
The novel GDNF variants of the present invention are preferably formulated as
pharmaceutical compositions administered by a variety of routes. Most preferably, such
GDNF variants are for parenteral or intracranial administration. Such pharmaceutical
compositions and processes for preparing same are well known in the art. See e.g.,
Remington: The Science and Practice of Pharmacy (A. Gennaro, et. al., eds., 19 ed.,
Mack Publishing Co., 1995).
A therapeutically effective amount is an amount of the novel GDNF variant of the
present invention necessary to impart a therapeutic benefit to the patient. It will be
understood that the amount of GDNF variant actually administered will be determined by
a physician, in light of the relevant circumstances, including the condition to be treated,
the chosen route of administration, the actual active agent administered, the age, weight,
and response of the individual patient, and the severity of the patient’s symptoms.
In this specification where reference has been made to patent specifications, other
external documents, or other sources of information, this is generally for the purpose of
providing a context for discussing the features of the invention. Unless specifically stated
otherwise, reference to such external documents is not to be construed as an admission
that such documents, or such sources of information, in any jurisdiction, are prior art, or
form part of the common general knowledge in the art.
The term “comprising” as used in this specification and claims means “consisting
at least in part of”. When interpreting statements in this specification, and claims which
include the term “comprising”, it is to be understood that other features that are additional
to the features prefaced by this term in each statement or claim may also be present.
Related terms such as “comprise” and “comprised” are to be interpreted in similar
manner.
SEQUENCE LISTING
<SEQ ID NO: 1; PRT1; Homo sapiens>
MKLWDVVAVCLVLLHTASAFPLPAGKRPPEAPAEDRSLGRRRAPFALSSDSNMP
EDYPDQFDDVMDFIQATIKRLKRSPDKQMAVLPRRERNRQAAAANPENSRGKGR
RGQRGKNRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYDKILKNL
SRNRRLVSDKVGQACCRPIAFDDDLSFLDDNLVYHILRKHSAKRCGCI
<SEQ ID NO: 2; DNA; Homo sapiens>
ATGAAGCTGTGGGACGTGGTGGCCGTGTGCCTGGTGCTGCTGCACACCGCCA
GCGCTTTCCCACTGCCAGCCGGCAAGAGACCCCCAGAGGCCCCAGCCGAGGA
CAGAAGCCTGGGCAGGCGGAGGGCCCCATTCGCCCTGAGCAGCGACAGCAAC
ATGCCAGAGGACTACCCCGACCAGTTCGACGACGTCATGGACTTCATCCAGG
CCACCATCAAGAGGCTGAAGAGGTCACCCGACAAGCAGATGGCCGTGCTGCC
CAGGCGGGAGAGGAACAGGCAGGCCGCCGCCGCCAACCCAGAGAATTCCAG
GGGCAAGGGCAGAAGGGGTCAACGGGGCAAGAACAGGGGCTGCGTGCTGAC
CGCCATCCACCTGAACGTGACCGACCTGGGCCTGGGCTACGAGACCAAGGAG
GAGCTGATCTTCAGGTACTGCAGCGGCAGCTGCGACGCCGCCGAGACCACCT
ACGACAAGATCCTGAAGAACCTGAGCAGGAACAGGCGGCTGGTCTCCGACAA
GGTGGGCCAGGCCTGCTGCAGGCCCATCGCCTTCGACGACGACCTGAGCTTC
CTGGACGACAACCTGGTGTACCACATCCTGAGGAAGCACAGCGCCAAGAGAT
GCGGCTGCATC
<SEQ ID NO: 3; PRT1; Homo sapiens>
SPDKQMAVLPRRERNRQAAAANPENSRGKGRRGQRGKNRGCVLTAIHLNVTDL
GLGYETKEELIFRYCSGSCDAAETTYDKILKNLSRNRRLVSDKVGQACCRPIAFD
DDLSFLDDNLVYHILRKHSAKRCGCI
<SEQ ID NO: 4; PRT1; Homo sapiens>
MKLWDVVAVCLVLLHTASA
<SEQ ID NO: 5; PRT1; Homo sapiens>
FPLPAGKRPPEAPAEDRSLGRRRAPFALSSDSNMPEDYPDQFDDVMDFIQATIKRL
KR
<SEQ ID NO: 6; DNA; Primer>
TATACATATGCGTGGACAACGTGGTAAAAACCGTGGTTGTGTGCTG
<SEQ ID NO: 7; DNA; Primer>
GGTGCTCGAGTTATTAAATGCAGCCGCAACGTTTCGCGCT
<SEQ ID NO: 8; PRT1; Homo sapiens>
RGQRGKNRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYDKILKNL
SRNRRLVSDKVGQACCRPIAFDDDLSFLDDNLVYHILRKHSAKRCGCI
<SEQ ID NO: 9; PRT1; Artificial Sequence>
RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYDKILKNL
SRNRRLVSEKVGQACCRPIAFDDDLSFLDDNLVYHILRKHSAKRCGCI
<SEQ ID NO: 10; DNA; Artificial Sequence>
ATGAAGCTGTGGGACGTGGTGGCCGTGTGCCTGGTGCTGCTGCACACCGCCA
GCGCTTTCCCACTGCCAGCCGGCAAGAGACCCCCAGAGGCCCCAGCCGAGGA
CAGAAGCCTGGGCAGGCGGAGGGCCCCATTCGCCCTGAGCAGCGACAGCAAC
45 ATGCCAGAGGACTACCCCGACCAGTTCGACGACGTCATGGACTTCATCCAGG
CCACCATCAAGAGGCTGAAGAGGTCACCCGACAAGCAGATGGCCGTGCTGCC
CAGGCGGGAGAGGAACAGGCAGGCCGCCGCCGCCAACCCAGAGAATTCCAG
GGGCAAGGGCAGAAGGGGTCAACGGGGCAAGCAGAGGGGCTGCGTGCTGAC
CGCCATCCACCTGAACGTGACCGACCTGGGCCTGGGCTACGAGACCAAGGAG
GAGCTGATCTTCAGGTACTGCAGCGGCAGCTGCGACGCCGCCGAGACCACCT
ACGACAAGATCCTGAAGAACCTGAGCAGGAACAGGCGGCTGGTCTCCGAGA
AGGTGGGCCAGGCCTGCTGCAGGCCCATCGCCTTCGACGACGACCTGAGCTT
CCTGGACGACAACCTGGTGTACCACATCCTGAGGAAGCACAGCGCCAAGAGA
TGCGGCTGCATC
<SEQ ID NO: 11; PRT1; Artificial Sequence>
MKLWDVVAVCLVLLHTASAFPLPAGKRPPEAPAEDRSLGRRRAPFALSSDSNMP
EDYPDQFDDVMDFIQATIKRLKRSPDKQMAVLPRRERNRQAAAANPENSRGKGR
RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYDKILKNL
SRNRRLVSEKVGQACCRPIAFDDDLSFLDDNLVYHILRKHSAKRCGCI
<SEQ ID NO: 12; PRT1; Artificial Sequence>
RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYDKILANL
SKNKRLVSEKVGQACCRPIAFDDDLSFLDDNLVYHILRKHSAKRCGCI
<SEQ ID NO: 13; DNA; Artificial Sequence>
ATGAAGCTGTGGGACGTGGTGGCCGTGTGCCTGGTGCTGCTGCACACCGCCA
GCGCTTTCCCACTGCCAGCCGGCAAGAGACCCCCAGAGGCCCCAGCCGAGGA
CAGAAGCCTGGGCAGGCGGAGGGCCCCATTCGCCCTGAGCAGCGACAGCAAC
ATGCCAGAGGACTACCCCGACCAGTTCGACGACGTCATGGACTTCATCCAGG
CCACCATCAAGAGGCTGAAGAGGTCACCCGACAAGCAGATGGCCGTGCTGCC
CAGGCGGGAGAGGAACAGGCAGGCCGCCGCCGCCAACCCAGAGAATTCCAG
GGGCAAGGGCAGAAGGGGTCAACGGGGCAAGCAGAGGGGCTGCGTGCTGAC
CGCCATCCACCTGAACGTGACCGACCTGGGCCTGGGCTACGAGACCAAGGAG
GAGCTGATCTTCAGGTACTGCAGCGGCAGCTGCGACGCCGCCGAGACCACCT
ACGACAAGATCCTGGCCAACCTGAGCAAGAACAAGCGGCTGGTCTCCGAGAA
GGTGGGCCAGGCCTGCTGCAGGCCCATCGCCTTCGACGACGACCTGAGCTTC
CTGGACGACAACCTGGTGTACCACATCCTGAGGAAGCACAGCGCCAAGAGAT
GCGGCTGCATC
<SEQ ID NO: 14; PRT1; Artificial Sequence>
MKLWDVVAVCLVLLHTASAFPLPAGKRPPEAPAEDRSLGRRRAPFALSSDSNMP
EDYPDQFDDVMDFIQATIKRLKRSPDKQMAVLPRRERNRQAAAANPENSRGKGR
RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYDKILANL
40 SKNKRLVSEKVGQACCRPIAFDDDLSFLDDNLVYHILRKHSAKRCGCI
<SEQ ID NO: 15; PRT1; Artificial Sequence>
RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYDKILANL
SKNKRLVSEKVGQACCRPIAFDDDLSFLDDNLVYHILREHSAKECGCI
<SEQ ID NO: 16; DNA; Artificial Sequence>
ATGAAGCTGTGGGACGTGGTGGCCGTGTGCCTGGTGCTGCTGCACACCGCCA
GCGCTTTCCCACTGCCAGCCGGCAAGAGACCCCCAGAGGCCCCAGCCGAGGA
CAGAAGCCTGGGCAGGCGGAGGGCCCCATTCGCCCTGAGCAGCGACAGCAAC
ATGCCAGAGGACTACCCCGACCAGTTCGACGACGTCATGGACTTCATCCAGG
CCACCATCAAGAGGCTGAAGAGGTCACCCGACAAGCAGATGGCCGTGCTGCC
CAGGCGGGAGAGGAACAGGCAGGCCGCCGCCGCCAACCCAGAGAATTCCAG
GGGCAAGGGCAGAAGGGGTCAACGGGGCAAGCAGAGGGGCTGCGTGCTGAC
CGCCATCCACCTGAACGTGACCGACCTGGGCCTGGGCTACGAGACCAAGGAG
GAGCTGATCTTCAGGTACTGCAGCGGCAGCTGCGACGCCGCCGAGACCACCT
ACGACAAGATCCTGGCCAACCTGAGCAAGAACAAGCGGCTGGTCTCCGAGAA
GGTGGGCCAGGCCTGCTGCAGGCCCATCGCCTTCGACGACGACCTGAGCTTC
CTGGACGACAACCTGGTGTACCACATCCTGAGGGAGCACAGCGCCAAGGAGT
GCGGCTGCATC
<SEQ ID NO: 17; PRT1; Artificial Sequence>
MKLWDVVAVCLVLLHTASAFPLPAGKRPPEAPAEDRSLGRRRAPFALSSDSNMP
EDYPDQFDDVMDFIQATIKRLKRSPDKQMAVLPRRERNRQAAAANPENSRGKGR
RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYDKILANL
SKNKRLVSEKVGQACCRPIAFDDDLSFLDDNLVYHILREHSAKECGCI
<SEQ ID NO: 18; DNA; Homo sapiens>
ATGAAGCTGTGGGACGTGGTGGCCGTGTGCCTGGTGCTGCTGCACACCGCCA
GCGCT
<SEQ ID NO: 19; DNA; Artificial Sequence>
ATGAAGCTGTGGGACGTGGTGGCCGTGTGCCTGGTGCTGCTGCACACCGCCA
GCGCTAGGGGTCAACGGGGCAAGCAGAGGGGCTGCGTGCTGACCGCCATCCA
CCTGAACGTGACCGACCTGGGCCTGGGCTACGAGACCAAGGAGGAGCTGATC
TTCAGGTACTGCAGCGGCAGCTGCGACGCCGCCGAGACCACCTACGACAAGA
TCCTGAAGAACCTGAGCAGGAACAGGCGGCTGGTCTCCGAGAAGGTGGGCCA
GGCCTGCTGCAGGCCCATCGCCTTCGACGACGACCTGAGCTTCCTGGACGAC
AACCTGGTGTACCACATCCTGAGGAAGCACAGCGCCAAGAGATGCGGCTGCA
TC
<SEQ ID NO: 20; PRT1; Artificial Sequence>
MKLWDVVAVCLVLLHTASARGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIF
RYCSGSCDAAETTYDKILKNLSRNRRLVSEKVGQACCRPIAFDDDLSFLDDNLVY
40 HILRKHSAKRCGCI
<SEQ ID NO: 21; DNA; Artificial Sequence>
ATGAAGCTGTGGGACGTGGTGGCCGTGTGCCTGGTGCTGCTGCACACCGCCA
GCGCTAGGGGTCAACGGGGCAAGCAGAGGGGCTGCGTGCTGACCGCCATCCA
45 CCTGAACGTGACCGACCTGGGCCTGGGCTACGAGACCAAGGAGGAGCTGATC
TTCAGGTACTGCAGCGGCAGCTGCGACGCCGCCGAGACCACCTACGACAAGA
TCCTGGCCAACCTGAGCAAGAACAAGCGGCTGGTCTCCGAGAAGGTGGGCCA
GGCCTGCTGCAGGCCCATCGCCTTCGACGACGACCTGAGCTTCCTGGACGAC
AACCTGGTGTACCACATCCTGAGGAAGCACAGCGCCAAGAGATGCGGCTGCA
TC
<SEQ ID NO: 22; PRT1; Artificial Sequence>
MKLWDVVAVCLVLLHTASARGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIF
RYCSGSCDAAETTYDKILANLSKNKRLVSEKVGQACCRPIAFDDDLSFLDDNLVY
HILRKHSAKRCGCI
<SEQ ID NO: 23; PRT1; Artificial Sequence>
RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYDKILXaa
NLSXaa NXaa RLVSEKVGQACCRPIAFDDDLSFLDDNLVYHILRXaa HSAKXaa
88 90 125
CGCI,
wherein:
i) Xaa is K or A;
ii) Xaa is R or K;
iii) Xaa is R or K;
iv) Xaa is K or E; and
v) Xaa is R or E.
<SEQ ID NO: 24; PRT1; Artificial Sequence>
MKLWDVVAVCLVLLHTASARGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIF
RYCSGSCDAAETTYDKILXaa NLSXaa NXaa RLVSEKVGQACCRPIAFDDDLSF
84 88 90
LDDNLVYHILRXaa HSAKXaa CGCI
125 130
wherein:
i) Xaa is K or A;
ii) Xaa is R or K;
iii) Xaa is R or K;
iv) Xaa is K or E; and
v) Xaa is R or E.
<SEQ ID NO: 25; PRT1; Mus musculus>
METDTLLLWVLLLWVPGSTG
<SEQ ID NO: 26; DNA; Mus musculus>
ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTTCCAGGATC
TACCGGT
<SEQ ID NO: 27; DNA; Artificial Sequence>
ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTTCCAGGATC
TACCGGTAGGGGTCAACGGGGCAAGCAGAGGGGCTGCGTGCTGACCGCCATC
CACCTGAACGTGACCGACCTGGGCCTGGGCTACGAGACCAAGGAGGAGCTGA
TCTTCAGGTACTGCAGCGGCAGCTGCGACGCCGCCGAGACCACCTACGACAA
GATCCTGAAGAACCTGAGCAGGAACAGGCGGCTGGTCTCCGAGAAGGTGGGC
CAGGCCTGCTGCAGGCCCATCGCCTTCGACGACGACCTGAGCTTCCTGGACG
ACAACCTGGTGTACCACATCCTGAGGAAGCACAGCGCCAAGAGATGCGGCTG
CATC
<SEQ ID NO: 28; PRT1; Artificial Sequence>
METDTLLLWVLLLWVPGSTGRGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIF
RYCSGSCDAAETTYDKILKNLSRNRRLVSEKVGQACCRPIAFDDDLSFLDDNLVY
HILRKHSAKRCGCI
<SEQ ID NO: 29; DNA; Artificial Sequence>
ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTTCCAGGATC
TACCGGTAGGGGTCAACGGGGCAAGCAGAGGGGCTGCGTGCTGACCGCCATC
CACCTGAACGTGACCGACCTGGGCCTGGGCTACGAGACCAAGGAGGAGCTGA
TCTTCAGGTACTGCAGCGGCAGCTGCGACGCCGCCGAGACCACCTACGACAA
GATCCTGGCCAACCTGAGCAAGAACAAGCGGCTGGTCTCCGAGAAGGTGGGC
CAGGCCTGCTGCAGGCCCATCGCCTTCGACGACGACCTGAGCTTCCTGGACG
ACAACCTGGTGTACCACATCCTGAGGAAGCACAGCGCCAAGAGATGCGGCTG
CATC
<SEQ ID NO: 30; PRT1; Artificial Sequence>
METDTLLLWVLLLWVPGSTGRGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIF
RYCSGSCDAAETTYDKILANLSKNKRLVSEKVGQACCRPIAFDDDLSFLDDNLVY
HILRKHSAKRCGCI
<SEQ ID NO: 31; PRT1; Artificial Sequence>
METDTLLLWVLLLWVPGSTGRGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIF
40 RYCSGSCDAAETTYDKILXaa NLSXaa NXaa RLVSEKVGQACCRPIAFDDDLSF
84 88 90
LDDNLVYHILRXaa HSAKXaa CGCI
125 130
wherein:
i) Xaa is K or A;
ii) Xaa is R or K;
iii) Xaa is R or K;
iv) Xaa is K or E; and
v) Xaa is R or E.
<SEQ ID NO: 32; PRT1; Homo sapiens>
MATGSRTSLLLAFGLLCLPWLQEGSA
<SEQ ID NO: 33; DNA; Homo sapiens>
ATGGCTACCGGCAGCAGGACCTCTCTGCTGCTGGCCTTCGGCCTGCTGTGCCT
GCCCTGGCTGCAGGAAGGCAGCGCC
<SEQ ID NO: 34; DNA; Artificial Sequence>
ATGGCTACCGGCAGCAGGACCTCTCTGCTGCTGGCCTTCGGCCTGCTGTGCCT
GCCCTGGCTGCAGGAAGGCAGCGCCAGGGGTCAACGGGGCAAGCAGAGGGG
CTGCGTGCTGACCGCCATCCACCTGAACGTGACCGACCTGGGCCTGGGCTAC
GAGACCAAGGAGGAGCTGATCTTCAGGTACTGCAGCGGCAGCTGCGACGCCG
CCGAGACCACCTACGACAAGATCCTGAAGAACCTGAGCAGGAACAGGCGGCT
GGTCTCCGAGAAGGTGGGCCAGGCCTGCTGCAGGCCCATCGCCTTCGACGAC
GACCTGAGCTTCCTGGACGACAACCTGGTGTACCACATCCTGAGGAAGCACA
GCGCCAAGAGATGCGGCTGCATC
<SEQ ID NO: 35; PRT1; Artificial Sequence>
MATGSRTSLLLAFGLLCLPWLQEGSARGQRGKQRGCVLTAIHLNVTDLGLGYET
KEELIFRYCSGSCDAAETTYDKILKNLSRNRRLVSEKVGQACCRPIAFDDDLSFLD
DNLVYHILRKHSAKRCGCI
<SEQ ID NO: 36; DNA; Artificial Sequence>
ATGGCTACCGGCAGCAGGACCTCTCTGCTGCTGGCCTTCGGCCTGCTGTGCCT
GCCCTGGCTGCAGGAAGGCAGCGCCAGGGGTCAACGGGGCAAGCAGAGGGG
CTGCGTGCTGACCGCCATCCACCTGAACGTGACCGACCTGGGCCTGGGCTAC
GAGACCAAGGAGGAGCTGATCTTCAGGTACTGCAGCGGCAGCTGCGACGCCG
CCGAGACCACCTACGACAAGATCCTGGCCAACCTGAGCAAGAACAAGCGGCT
GGTCTCCGAGAAGGTGGGCCAGGCCTGCTGCAGGCCCATCGCCTTCGACGAC
GACCTGAGCTTCCTGGACGACAACCTGGTGTACCACATCCTGAGGAAGCACA
GCGCCAAGAGATGCGGCTGCATC
40 <SEQ ID NO: 37; PRT1; Artificial Sequence>
MATGSRTSLLLAFGLLCLPWLQEGSARGQRGKQRGCVLTAIHLNVTDLGLGYET
KEELIFRYCSGSCDAAETTYDKILANLSKNKRLVSEKVGQACCRPIAFDDDLSFLD
DNLVYHILRKHSAKRCGCI
<SEQ ID NO: 38; PRT1; Artificial Sequence>
MATGSRTSLLLAFGLLCLPWLQEGSARGQRGKQRGCVLTAIHLNVTDLGLGYET
KEELIFRYCSGSCDAAETTYDKILXaa NLSXaa NXaa RLVSEKVGQACCRPIAF
84 88 90
DDDLSFLDDNLVYHILRXaa HSAKXaa CGCI
125 130
wherein:
i) Xaa is K or A;
ii) Xaa is R or K;
iii) Xaa is R or K;
iv) Xaa is K or E; and
v) Xaa is R or E.
<SEQ ID NO: 39; DNA; Primer>
TATACATATGCGTGGACAACGTGGTAAACAACGTGGTTGTGTGCTG
<SEQ ID NO: 40; DNA; Primer>
GGTGCTCGAGTTATTAAATGCAGCCGCAACGTTTCGCGCT
<SEQ ID NO: 41; DNA; Primer>
GTCTGGTGAGCGAGAAAGTGGGTCAG
<SEQ ID NO: 42; DNA; Primer>
CTGACCCACTTTCTCGCTCACCAGAC
<SEQ ID NO: 43; DNA; Primer>
CCTATGATAAAATCCTGGCAAACCTGAGCAAGAACAAACGTCTGGTGAGCGA
GAAAG
<SEQ ID NO: 44; DNA; Primer>
40 CTTTCTCGCTCACCAGACGTTTGTTCTTGCTCAGGTTTGCCAGGATTTTATCAT
SEQ ID NO: 1: AA-Human GDNF wild type full length
SEQ ID NO: 2: DNA- Human GDNF wild type full length
SEQ ID NO: 3: AA- Human Mature wild type GDNF
SEQ ID NO: 4: AA- Human GDNF native secretion signal peptide
SEQ ID NO: 5: AA- Human GDNF Pro-domain
SEQ ID NO: 6: DNA – ∆31-for Primer
SEQ ID NO: 7: DNA- ∆31-rev Primer
SEQ ID NO: 8: AA-Variant 1: Delta-31 GDNF
SEQ ID NO: 9: AA- GDNF variant 2: ∆31+N38Q+D95E (clone D9) protein (103aa)
SEQ ID NO: 10: DNA construct sequence- GDNF variant 2: ∆31+N38Q+D95E (clone
D9) DNA(pEE12.4)
SEQ ID NO: 11: AA- GDNF variant 2: ∆31+N38Q+D95E (clone D9) protein construct
(211aa).
SEQ ID NO: 12: AA- GDNF variant 3: ∆31 + N38Q+K84A-R88K-R90K-D95E (clone
F2.1) protein sequence (103aa)
SEQ ID NO: 13: DNA construct sequence-GDNF variant 3: ∆31 + N38Q+K84A-R88K-
R90K-D95E (clone F2.1) DNA sequence
SEQ ID NO: 14: AA- GDNF variant 3: ∆31 + N38Q+K84A-R88K-R90K-D95E (clone
F2.1) protein construct (211aa)
SEQ ID NO: 15: AA- GDNF variant 4: ∆31 + N38Q+K84A-R88K-R90K-D95E +
K125E + R130E (clone 4.3) protein sequence (103aa):
SEQ ID NO: 16: DNA construct sequence- GDNF variant 4: ∆31 + N38Q+ K84A-
R88K-R90K-D95E + K125E + R130E (clone 4.3) DNA sequence
SEQ ID NO: 17: AA- GDNF variant 4: ∆31 + N38Q+K84A-R88K-R90K-D95E +
K125E + R130E (clone 4.3) protein construct
SEQ ID NO: 18: DNA- Human GDNF native secretion signal peptide
SEQ ID NO: 19: DNA-Native Peptide -Delta-31 N38Q+D95E Construct
SEQ ID NO: 20: AA- Native Peptide-Delta-31 N38Q+D95E (122aa):
SEQ ID NO: 21: DNA- Native Peptide-Delta-31 N38Q+K84A-R88K-R90K-D95E
SEQ ID NO: 22: AA- Native Peptide-Delta-31 N38Q+K84A-R88K-R90K-D95E
(122aa):
SEQ ID NO: 23: AA-consensus sequence of variants
SEQ ID NO: 24: AA-Native Peptide-consensus sequence of variants
SEQ ID NO: 25: AA- Murine Kappa Leader Secretion Signal Peptide (MKL)
SEQ ID NO: 26: DNA- Murine Kappa Leader Secretion Signal Peptide (MKL)
SEQ ID NO: 27: DNA- MKL-Delta-31 N38Q+D95E Construct
SEQ ID NO: 28: AA- MKL-Delta-31 N38Q+D95E (123aa):
SEQ ID NO: 29: DNA-MKL-Delta-31 N38Q+K84A-R88K-R90K-D95E Construct
40 SEQ ID NO: 30: AA-MKL-Delta-31 N38Q+K84A-R88K-R90K-D95E (123aa):
SEQ ID NO: 31: AA-Murine Kappa Leader-consensus sequence of variants
SEQ ID NO: 32: AA- Human Growth Hormone Secretion Signal Peptide (hGH)
SEQ ID NO: 33: DNA- Human Growth Hormone Secretion Signal Peptide (hGH)
SEQ ID NO: 34: DNA- hGH-Delta-31 N38Q+D95E Construct
45 SEQ ID NO: 35: AA- hGH-Delta-31 N38Q+D95E (129aa):
SEQ ID NO: 36: DNA- hGH-Delta-31 N38Q+K84A-R88K-R90K-D95E Construct
SEQ ID NO: 37: AA- hGH-Delta-31 N38Q+K84A-R88K-R90K-D95E (123aa):
SEQ ID NO: 38: AA-hGH-consensus sequence of variants
SEQ ID NO: 39: DNA - ∆31-N38Q-for Primer
SEQ ID NO: 40: DNA - ∆31-N38Q-rev Primer
SEQ ID NO: 41: DNA - ∆31-N38Q-D95E-for Primer
SEQ ID NO: 42: DNA - ∆31-N38Q-D95E-rev Primer
SEQ ID NO: 43: DNA - ∆31-N38Q-KAKKE-for Primer
SEQ ID NO: 44: DNA - ∆31-N38Q-KAKKE-rev Primer
WE
Claims (20)
1. A human GDNF variant comprising the amino acid sequence of SEQ ID NO:23: 5 RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYD KILXaa NLSXaa NXaa RLVSEKVGQACCRPIAFDDDLSFLDDNLVYHI 84 88 90 LRXaa HSAKXaa CGCI 125 130 wherein: i) Xaa is K or A; 10 ii) Xaa is R or K; iii) Xaa is R or K; iv) Xaa is K or E; and v) Xaa is R or E.
2. The human GDNF variant as claimed by Claim 1 wherein said variant is 15 selected from the group consisting of RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYD KILKNLSRNRRLVSEKVGQACCRPIAFDDDLSFLDDNLVYHILRKHSAK RCGCI (SEQ ID NO:9), RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYD 20 KILANLSKNKRLVSEKVGQACCRPIAFDDDLSFLDDNLVYHILRKHSAK RCGCI (SEQ ID NO:12), and RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYD KILANLSKNKRLVSEKVGQACCRPIAFDDDLSFLDDNLVYHILREHSAK ECGCI (SEQ ID NO:15). 25
3. The human GDNF variant as claimed by Claim 2 wherein said variant is RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYD KILKNLSRNRRLVSEKVGQACCRPIAFDDDLSFLDDNLVYHILRKHSAK RCGCI (SEQ. ID: 9).
4. The human GDNF variant as claimed by Claim 2 wherein said variant is 30 RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYD KILANLSKNKRLVSEKVGQACCRPIAFDDDLSFLDDNLVYHILRKHSAK RCGCI (SEQ ID NO:12).
5. The human GDNF variant as claimed by Claim 2 wherein said variant is RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYD 5 KILANLSKNKRLVSEKVGQACCRPIAFDDDLSFLDDNLVYHILREHSAK ECGCI (SEQ ID NO:15).
6. A compound comprising an amino acid sequence selected from the group consisting of METDTLLLWVLLLWVPGSTGRGQRGKQRGCVLTAIHLNVTDLGLGYET 10 KEELIFRYCSGSCDAAETTYDKILKNLSRNRRLVSEKVGQACCRPIAFDD DLSFLDDNLVYHILRKHSAKRCGCI (SEQ ID NO: 28); and MATGSRTSLLLAFGLLCLPWLQEGSARGQRGKQRGCVLTAIHLNVTDL GLGYETKEELIFRYCSGSCDAAETTYDKILKNLSRNRRLVSEKVGQACC RPIAFDDDLSFLDDNLVYHILRKHSAKRCGCI (SEQ ID NO: 35). 15
7. A compound as claimed by Claim 6 wherein the amino acid sequence is MATGSRTSLLLAFGLLCLPWLQEGSARGQRGKQRGCVLTAIHLNVTDL GLGYETKEELIFRYCSGSCDAAETTYDKILKNLSRNRRLVSEKVGQACC RPIAFDDDLSFLDDNLVYHILRKHSAKRCGCI (SEQ ID NO: 35).
8. A pharmaceutical composition comprising a human GDNF variant as claimed 20 by any one of Claims 1 to 5 and one or more pharmaceutically acceptable diluents, carriers or excipients.
9. Use of a human GDNF variant as defined in any one of Claims 1 to 5 in the manufacture of a medicament for treating Parkinson’s disease in a human patient in need thereof. 25
10. Use of a pharmaceutical composition as defined in Claim 8 in the manufacture of a medicament for treating Parkinson's disease in a human patient in need thereof.
11. The use of Claim 9 or 10 wherein the medicament comprises an effective amount of the human GDNF variant.
12. A human GDNF variant as claimed by any one of Claims 1 to 5 for use as a medicament.
13. A human GDNF variant as claimed by any one of Claims 1 to 5 for use in the treatment of Parkinson’s disease. 5
14. Use of a human GDNF variant as claimed by any one of Claims 1 through 5 in the manufacture of a medicament for treating Parkinson’s disease in a mammal
15. The use of claim 14 wherien the medicament comprises an effective amount of the human GDNF variant. .
16. A human GDNF variant as claimed by any one of Claims 1 through 5 for use as 10 a therapy.
17. A human GDNF variant as defined in any one of Claims 1 to 5, 12, 13 and 16 substantially as herein described with reference to any example thereof.
18. A compound as defined in Claim 6 or 7 substantially as herein described with reference to any example thereof. 15
19. A pharmaceutical composition as defined in Claim 8 substantially as herein described with reference to any example thereof.
20. A use as defined in any one of Claims 9 to 11, 14 and 15 substantially as herein described with reference to any example thereof. 5706153_1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161474024P | 2011-04-11 | 2011-04-11 | |
US61/474,024 | 2011-04-11 | ||
PCT/US2012/031927 WO2012141936A1 (en) | 2011-04-11 | 2012-04-03 | Variants of human gdnf |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ614325A NZ614325A (en) | 2015-07-31 |
NZ614325B2 true NZ614325B2 (en) | 2015-11-03 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9493530B2 (en) | FGF21 mutants comprising a mutation at position 98, 171 and/or 180 | |
US8835385B2 (en) | FGF21 polypeptides comprising two or more mutations and uses thereof | |
US7696172B2 (en) | Fibroblast growth factor-like polypeptides | |
TW201408693A (en) | Fibroblast growth factor 21 proteins | |
US9243046B2 (en) | Variants of human GDNF | |
NZ614325B2 (en) | Variants of human gdnf |